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AML Acute myeloid leukemia
BMI Body mass index
BSA Body surface area, an indicator for metabolic mass in the body 
calculated using e.g. Du Bois formula: BSA = 0.007184 x 
Weight0.425 x Height0.725     
CD Cluster of differentiation (cell surface target for immune typing)
CON Healthy age and gender matched individuals included in the study
COX Cyclooxygenase 
CTCAE Common Terminology Criteria for Adverse Events of The National 
Cancer Institute (NCI) of the National Institutes of Health (NIH)
DC Dendritic cell 
DNA Deoxyribonucleic acid
DRYD Dihydropyrimidine dehydrogenase
ECOG Eastern cooperative oncology group performance status 
EGFR Epithelial growth factor receptor
FDG-PET/CT Flour-Deoxy-Glucose-Positron-Emissions-Tomography/CT scan
FDR False discovery rate 
FFPE Formalin fixed, paraffin embedded 
GCSF Granulocyte-colony stimulating factor
GGE Global gene expression
GM Gastro-intestinal mucositis
H&E Hematoxylin eosin stain 
HER-2 Human epidermal growth factor
HNC Head and neck cancer
HSCT High dose chemotherapy supported with stem cell transplantation
HLA Human leucocyte antigen 
IL Interleukin 
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IMRT Intensity modulated radiation therapy 
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JNK Jun-N-terminal
MASCC Multinational Association of Supportive Care in Cancer
MAPK Mitogen activated protein kinase 
MHC Major Histocompatibility Complex 
MM Multiple myeloma 
MMP Matrix metalloproteinase
MNC Mononuclear cells 
MOMP Mitochondrial outer membrane permeability 
mRNA Messenger-RNA
NCI National Cancer Institute
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NK-cells Natural killer cells
NM None/mild mucositis
NSCLC Non-small cell lung cancer
OM Oral mucositis
PCR Polymerase chain reaction
ROS Reactive oxygen species
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyses
RT Radiation treatment
SNP Single nucleotide polymorphism
snRNA Small nuclear RNA
TKI Tyrosine kinase inhibitor
TNFα Tumor necrosis factor alpha
TSCC Tonsil squamous cell carcinoma
UM Ulcerative mucositis
VEGF Vascular endothelial growth factor
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PREFACE
Mucositis of the oral and gastro-intestinal mucosa is one of the most painful side 
effects of cancer treatment. Clinically it is defined as a state of mucosal 
inflammation with characteristics that allow graduation in accordance with 
objective signs and subjective claims, including erythema, ulcerations, pain, nausea 
and diarrhea. The severely affected patients spend prolonged time in hospital. 
Knowledge of the molecular reactions that underlie mucositis has evolved primarily
from animal models, based on the assumption that mucositis is one entity clinically
and independent of disease and patients characteristics. In these models, potential 
preventive interventions were tested with promising results; however, only few 
interventions and no predictive tests were translated into clinical practice. 
A systematic review of the literature (Manuscript I) exposed only a limited number 
of human studies and even fewer including a correlation to clinical mucositis,
indicated the need to link clinical data with molecular events in the epithelium.
Therefore, we proposed a simple model to conduct a number of comparable 
scientific pilot studies in three different cancer treatment regimens known to induce 
mucositis. 
The working hypothesis of this study was that molecular analysis of consecutive 
human mucosa biopsies and peripheral blood samples would reveal molecular 
mechanisms of importance to our understanding of the mucositis pathogenesis. We 
aimed to answer following specific scientific questions:
 Was the study program and model feasible?
 Could we identify specific molecular changes in human mucosa and blood
samples over time during cancer treatment?
 Were these changes correlated to mucositis severity?
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 Could we identify disease and/or treatment specific gene expression 
patterns? 
We correlated the gene expression profiles of consecutive mucosa tissue and blood 
cell samples before, during, and after treatment with the grade of clinical mucositis 
among small groups of patients with multiple myeloma (MM), acute myeloid 
leukemia (AML), and tonsil squamous cell carcinoma (TSCC). The results of these
studies are reported in Manuscripts II-IV and yielded the following main results: 
 The study was feasible with sufficient tissue quality and no clinical 
complications observed.
 In response to therapy, we found genes altered in the mucosa tissues
dominated by DNA damage, DNA defense and repair in all three groups
with no identified correlation to grade of clinical mucositis.
 Differences among the groups were apparent; e.g., early immune 
regulation was seen only in MM and TSCC but not in AML mucosa. 
 In MM, pretreatment expression of the genes HLA-DR1 and HLA-DRB5
were potential predictive protective biomarkers for ulcerative mucositis. 
 In TSCC, pretreatment expression of the gene LY6G6C was a potential 
predictive protective biomarker for ulcerative mucositis. 
 A principal component analysis of the global dataset on mucosal gene 
expression revealed that patients cluster according to disease indicating 
that disease is foremost contributor to the variation in gene expression of 
the mucosa samples and not mucositis grade.
 In brief, this pilot study presents a feasible model and preliminary results 




Mukositis i mundslimhinden og i mave- tarmkanalen, er en af de mest smertefulde
bivirkninger ved kræftbehandling. Mukositis ses klinisk udtrykt i varierende
sværhedsgrad hos patienter, der modtager sammenlignelig behandling. De patienter 
som rammes i svær grad oplever udbredt sårdannelse i mund og svælg, opportunistiske 
infektioner, opkastning og diarre og indlæggelsestiden for disse patienter øges.
Viden om de molekylære reaktioner i mucosa under kræftbehandling er primært 
udledt fra dyre eksperimentelle studier ud fra den formodning, at mukositis er 
klinisk varierende og udelukkende afhængig af behandlingsregime. Lovende fund
fra disse studier kunne ikke overføres til klinikken og der findes fortsat ingen 
forebyggende behandling eller prædiktive tests for patienter med svær mukositis. 
Baseret på et systematisk litteraturstudie (Manuskript I), som belyste, at der kun er 
udført få studier om de molekylære reaktioner i human mukosa under 
kræftbehandling, afdækkede vi et behov for at sammenholde de molekylære 
reaktioner i vævet med det kliniske udtryk af mucositis. Vi foreslog derfor en 
simpel model af sammenlignelige pilotstudier i tre forskellige kræft 
behandlingsregimer, hvor mucosa og blod fra patienter blev analyseret. 
Derfor blev arbejdshypotesen for dette studie at molekylær analyse af 
slimhindebiopsier og blodceller før, under og efter kræftbehandling ville afsløre 
sammenhænge, der kunne bidrage til vores forståelse af mukositis patogenesen. Vi 
søgte at besvare følgende spørgsmål: 
 Er det muligt at foretage konsekutive biopsier med acceptabelt væv til 
molekylær analyser uden komplikationer?
 Kan vi identificere specifikke molekylære ændringer i mucosa og blod over tid 
hos patienter i kræftbehandling?
 Er disse ændringer korreleret til graden af klinisk mukositis?
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 Findes sygdoms eller behandlings specifikke biomarkører?
Herefter gennemførte vi tre parallelle kliniske studier med indsamling af mucosa
biopsier og blodprøver fra patienter før, under og efter kræftbehandling. Vi 
inkluderede patienter med henholdsvis knoglemarvskræft (myelomatose, MM), 
akut myeloid leukæmi (AML) og tonsilkræft (TSCC). Vi udførte gen ekspressions 
analyse af mucosa og blod og korrelerede resultaterne til graden af klinisk 
mucositis. Resultaterne er rapporteret i Manuskript II-IV: 
 Den opstillede forsøgsmodel gav sufficient væv til genanalyse og var uden 
kliniske komplikationer.
 Som reaktion på behandling, fandt vi opregulering af gener relateret til
apoptose, DNA skade og reparation, i alle tre behandlingsgrupper. Der var også 
forskelle mellem grupperne; f.eks. sås tidlig involvering af immunsystemet kun 
i TSCC og MM gruppen. 
 Vi kunne ikke identificere tilsvarende ændringer i blodet. 
 Disse op- og nedregulerede gener var uafhængig af mucositis grad.
 Vi fandt at generne HLA-DRB1 og HLA-DRB5 var potentielle prædiktive
biomarkører for svær mucositis hos patienter med MM. 
 Vi fandt at genet LY6G6C var en potentiel prædiktive biomarkør for svær 
mucositis hos TSCC.
 En principal komponent analyse af det samlede datasæt for genekspressions i 
mukosa viste at patienterne clustrer omkring sygdom, der således bidrager med 
den største variation i ekspression mere end mucositis grad. 
 Kort fortalt, dette studie viser en brugbar model til i fremtiden at identificere 
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Mucositis is an acute and potentially dose limiting side effect of cancer treatment,
and present clinically as inflammation of the oral and gastro-intestinal mucosa
(1,2). Generally, 2-3 days following the administration of chemotherapy, gastro-
intestinal mucositis (GM) may present as abdominal bloating, vomiting, diarrhea 
and/or constipation (3,4) and after 7-10 days oral mucositis (OM) may present as 
erythema and/or ulcers of the oral mucosa (Fig 1) (5–8). The inflammation resolves 
spontaneously one to two weeks after termination of treatment (9,10). Radiation 
therapy (RT) induced mucositis is dose dependent, restricted to the radiation field 
and appear after a cumulative dose of 30-35 grey; concomitant chemotherapy 
aggravates the condition (11–13). Targeted therapy also induces mucositis. The oral 
affections resemble aphtous lesions and may be accompanied by a skin rash, but
gastro-intestinal symptoms are more common in this group (14–16). 
Fig 1. The clinical presentation of severe/ulcerative oral mucositis: confluent painful patches of ulcers 
impair oral food intake and parenteral feeding may become necessary. Ulcers are the entrance of 
bacteria and fungi that may cause potential lethal infections. From Sonis 2004 (17). 
Cancer therapy also affects the microflora by reducing the diversity and load, which 
may lead to opportunistic infections and reactivation of latent viruses (18–24).
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Mucositis is unevenly expressed among patients and the clinical manifestations
have been described in several studies (5,6,14,25). Compared to mild mucositis, 
severe mucositis is associated with mucosal ulcers, fever, diarrhea, nausea, 
vomiting, and opportunistic infections. Patients with severe mucositis generally 
require prolonged hospitalization, need stronger pain relief, feeding tube
installation, and intensive care (25–28). Consequently, severe mucositis continues 
to be a considerable burden to patients and to the healthcare system (29).
The evaluation of clinical oral mucositis is standardized across cancer treatment 
regimens (30). The anatomical location and the visual presentation of the mucosa
(erythema, ulceration) combined with registration subjective symptoms (pain, 
mouth dryness, inability to eat solid food) is summed up in a scale. The most 
widely used is oral mucositis toxicity scale (range 0-4) of The World Health 
Organization (WHO) (Appendix A, Table 1). A graduation of 0-1 indicate no/mild 
mucositis (NM), whereas at ratings of 2-4, termed ulcerative mucositis (UM), 
patients are gradually unable to swallow food and may need parenteral feeding. The 
Common Terminology Criteria for Adverse Events (CTCAE) issued by the 
National Cancer Institute (NCI) is available for GM scoring on a five level scale
(Appendix A, Table 2). At graduations of 1 to 2 vomiting raises from one to two 
episodes in 24 hours to three to five episodes. Grade 3 indicates more than 6 
episodes, whereas grades 4 to 5 are life-threatening gradually leading to death (31).
1.2. INCIDENCE AND RISK FACTORS 
The incidence of mucositis is closely related to drug regimen (14,27,32–37), and 
the strongest mucositis risk factor is the type of cancer treatment (38). Among 
patients with head and neck cancer (HNC) that receive combined chemo-radiation 
therapy the incidence is 85%, even with the implementation of intensity modulated 
radiation therapy (IMRT) (2,39,40). Although radiation treatment (RT) is generally 
performed as an out-patient treatment, hospitalization is needed in 37%, and a 
feeding tube is indicated in 51% of these patients (2,26). Among patients with 
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hematologic cancers, mucositis is generally frequent, and of the patients in high 
dose chemotherapy receiving autologous stem cell transplantation (HSCT) 80% are 
affected to some degree, although only 40% severely (27). Among patients with 
solid tumors in conventional chemotherapy the overall risk is 5 to 40% (41). In 
patients that receive targeted therapy mucositis is also frequent, however, skin rash 
and gastro-intestinal symptoms are more common (14,42,43). Mucositis was
reported in 66% of patients receiving the anti-mTOR agent Rapamycin (44)
whereas skin rash and diarrhea was reported in up to 80% in patients treated with 
the tyrosine kinase inhibitor (TKI) Erlotinib (45). A combination of different 
regimens as well as targeted agents seem to have an additive effect (15,46,47) and
children generally have a higher risk of developing mucositis compared to adults 
(33). 
Patient-related risk factors include increased dose per kilogram body weight (low 
body mass index (BMI)), female gender and baseline eastern cooperative oncology 
group performance status (ECOG) including reduced renal function (27,48). The 
susceptibility to mucositis expressed in both female gender and children relates to 
the body surface area (BSA), an indicator of metabolic body mass, from which the 
dosage of a chemotherapeutic drug is estimated (men 1.9; female 1.6; child 10 yrs. 
1.1). Low BSA/bodyweight is positively related to mucositis (5).
A genetic component also seem to be associated with UM. Patients with the 
autoimmune disease psoriasis are 70% less prone to severe mucositis (1,49). 
Genomic polymorphisms in genes encoding drug-metabolizing enzymes are 
associated with higher risk of severe mucositis. For example, certain single 
nucleotide polymorphisms (SNP) of dihydropyrimidine dehydrogenase (DPYD) 
that degrades Capecitabine to 5-Fluorouracil (5-FU) may predict severe mucositis.
The topoisomerase inhibitor Irinotecan cause severe neutropenia and diarrhea in 
patients expressing less of the UGT1A1*28 allele. Furthermore, polymorphisms in 
genes encoding the proteins p53 or MDM2 in patients with advanced non-small cell 
lung cancer (NSCLC) treated with platinum-based chemotherapy which is now a
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U.S. Food and Drug Administration (FDA) approved predictor of severe irinotecan 
toxicity, although controversy still exists (50–56). 
DNA extracted from the saliva of 216 patients suffering various hematologic 
malignancies and treated with HSCT, was examined for SNPs associated with 
mucositis severity, and a Bayesian network was built This network could predict 
severe mucositis with a predictive validity of 81.2% (57). A second similar study
included 972 patients with multiple myeloma in HSCT treatment, and eleven SNPs 
located near matrix metalloproteinase (MMP) 13 was associated with UM (58).
1.3. RECOMMENDATIONS OF CARE 
Based on a systematic literature review, The Multinational Association of 
Supportive Care in Cancer and International Society of Oral Oncology 
(MASCC/ISOO) regularly issue Clinical Practice Guidelines for oral and gastro-
intestinal mucositis (59). First, there is a general suggestion in favor of using an oral 
care protocol for the prevention of oral mucositis across all cancer treatment 
regimens. Other recommendations are treatment specific; 30 min of oral 
cryotherapy prevent oral mucositis in patients receiving 5-FU bolus; benzydamine 
mouthwash prevent oral mucositis in patients with HNC receiving moderate doses 
RT (less than 50 Gy), without concomitant chemotherapy. Although not reducing 
the incidence of mucositis, treatment of pain is mandatory. For HSCT patients self-
administered morphine for pain relief is recommended, and transdermal fentanyl at 
levels of 50 μg/h is suggested (60). For patients receiving chemo-radiation for 
HNC, a 2% morphine mouthwash for reliving for OM is suggested (60). Finally, 
patients in cancer treatment receive a broad spectrum of antibiotics, antifungal,
and/or anti-viral prescriptions to prevent opportunistic infections (39,60–63). 
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1.4. MOLECULAR BIOLOGY OF MUCOSITIS
The current model of mucositis pathology describe how chemotherapy and/or RT
initially inflict DNA damage on the endothelium and the rapidly dividing cells in 
the basal layer of the epithelium (64–67). Intrinsic apoptotic pathways are up-
regulated by reactive oxygen species (ROS), pro-apoptotic regulators BAX/BAK 
and p53 (68–71). Simultaneously, chemotherapy and/or RT trigger pro-
inflammatory cytokines, tumor necrosis factor alpha (TNFα), interleukin (IL) 1-
beta, and IL-6 to enter the circulation (6,72–74), that lead to the activation of an 
inflammatory response via nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB). This process damage the molecular parts of the submucosa (75). 
TNFα activates the extrinsic apoptotic pathway via mitogen activated protein kinase 
(MAPK), Ceramide, and SAPK/Jun (76–78). NF-κB activated COX-2 facilitates 
prostaglandin productions, while TNFα activates NF-κB and c-JUN in a feedback 
mechanism leading to apoptosis. Inflammatory infiltration and bacterial 
colonization lead to further tissue damage, which involves among others MMP, 
which was recently identified as a key regulator of mucositis (79–81). Barrier 
function and mucosal integrity is compromised through disruption of tight junctions 
(82,83). COX-2 initiate angiogenesis and macrophage recruitment down-regulates 
the inflammatory response (84,85); the production of new tissue results in healing. 
Studies reporting global gene expression (GGE) analysis on mucositis were 
introduced in animal models (86). Following irradiation (35 Gy applied once to the 
cheek pouch of hamsters), tissue was secured after one, 4, 8 and 24 hours, 5 and 10 
days. Within 8 hours, 10 genes related to acute tissue damage were identified. 
Among these MAPK, Hsp70, KRT14 and SPRR8 were up-regulated. Neither NF-κB 
nor TNFα were altered before day 10. In a mouse model, 15 Gy was applied to the 
snout, and the tissues were analyzed before, at day 1, 3, 5, 7, 10, 14, 21 and 28 (87). 
Generally, the expression of IL-6, IL-1β, TNFα, C-X-C motif ligand 1 (CXCL1)
and C-C motif ligand 2 (CCL2) gradually increased until day 7 and rapidly 
decreased hereafter. Suppression of p53 was found in another radiation mouse 
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model (83). Most recently, the importance of the epithelial mast cell was examined 
in a rat model (88). Pathways of anti-inflammatory signaling were up-regulated in 
the immune competent rats, seemingly protecting against radiation injury whereas 
the incompetent rats were injured more seriously. 
In a model of Irinotecan-treated rats, biopsies from different parts of the gastro-
intestinal tract at various time points, were analyzed (0 to 72 hours). More than 500 
genes were temporarily altered (76,89,90); among these, an early response of the 
genes involved in stress response, apoptosis, cell cycle, and transcription. The most 
dominant pathways were the MAPK, cell cycle, keratinocyte differentiation, B-cell 
receptor, and apoptotic signaling pathways. The inflammatory pathways NF-κB, 
Jun, Il-6, TNFα and Bax were up-regulated early. This study also showed that 
similar pathways were activated in the different anatomic regions of the oral and 
gastro-intestinal canal. In a recent study on transgenic mice receiving 100 mg/kg 5-
FU, gene expression analysis of the intestinal mucosa also revealed a central role of 
NF-κB (91). In a mice model using Doxorubicin in different doses, apoptosis was
observed within one day (92). In addition, the expression of caspase and TCF-4 (a 
WNT-signaling pathway transcription factor) increased whereas bone morphogen
protein (BMP) 4 decreased. Both TCF-4 and BMP4 are involved in the regulation 
of stem cell proliferation and homeostasis in the epithelial-mesenchymal 
compartment. 
1.5. CELLULAR STRESS, APOPTOSIS AND TARGETS FOR 
CYTOTOXIC AGENTS 
Most conventional chemotherapeutic drugs, radiation and some targeted therapy 
agents activate the apoptotic pathways through DNA damage (68,93–96). 
Apoptosis is a genetically determined process of programmed cell death and is a 
part of normal development and elimination of damaged and unusable cells and of
pathological conditions (97). Two classical signaling pathways induce apoptosis
(Fig 2). The intrinsic apoptotic pathway is activated by stress factors and physical 
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or chemical injuries, i.e., hypoxia, radiation, heat shock, aggregation of misfolded 
proteins or disruption of the cytoskeleton (98). ROS released through mitochondrial 
outer membrane permeability (MOMP) into the cytoplasm activates a cascade of 
pro-apoptotic factors, e.g., BCL2 family, p53 and BAX/BAK. The extrinsic or 
receptor-mediated apoptotic pathway is initiated by an external death ligands of the 
TNF family (e.g. TNFα, FasL, and TRAIL) situated in the outer cell membrane. 
These ligands stimulate death receptors e.g., TNFR1, FasR-alfa DR3. Both 
apoptotic pathways eventually activate caspase, an apoptosis initiating protease. 
Cytotoxic T lymphocytes and natural killer cells (NK-cells) may activate a third 
pathway in which granzyme A and B activate procaspase.
Among the therapies that induce apoptosis are radiation, the alkylating agents (e.g., 
melphalan, bulsulfan, cisplatin), antimicrotubule agents (e.g., vincristine, 
vinblastine), anti-metabolites (e.g., methotrexate, fluorouracil, cytarabine), 
topoisomerase inhibitors (irinotecan, etoposide), cytotoxic antibiotics (doxorubicin 
and daunorubicin) and some targeted agents (e.g. bortezomib, trastuzumab) (46,99–
101). Other targeted therapies (monoclonal antibodies and TKI inhibitors) act
through the inhibition or blocking of specific molecular targets, e.g., human 
epidermal growth factor (HER-2), epithelial growth factor receptor (EGFR), or 
vascular endothelial growth factor (VEGF) (14,15,42).
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Fig 2. Apoptotic pathways. The intrinsic apoptotic pathway is activated by stress factors and physical or 
chemical injuries, i.e., hypoxia, radiation, heat shock, aggregation of misfolded proteins or disruption of 
the cytoskeleton. The extrinsic or receptor-mediated apoptotic pathway is initiated by an external death 
ligand of the tumor necrosis factor (TNF) family (e.g. TNFα, FasL, and TRAIL). Both pathways activate 
the final apoptosis inducer caspase3.
1.6. ANATOMY OF THE ORAL MUCOSA
Mucosa is a stratified layer of squamous cells either keratinized or non-keratinized. 
Compared to other tissues of the body the turnover rate of the continuously 
proliferating epithelial cells is high, estimated 4-5 days, compared to 39 days for 
normal skin (102,103). From the basal stem cell layer asymmetric division is 
followed by symmetric division and amplification and finally post mitotic
differentiation (104–107) (Fig 3). 
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Fig 3. A schematic drawing of normal mucosa anatomy. Left: The white area indicates the 
submucosa/connective tissue compartment consisting of fibroblasts, muscle, glands, vessels and nerve 
fibers. A: Stem cell compartment of the basal layer for continuous differentiation (positive for keratin 15 
and 19). B: Early differentiated epithelial cells (positive for keratin 6 and 16). C: Supra basal layer of 
keratinized or non-keratinized cells. From Dabelsteen 2006 (104). Right: The basal stem cell layer 
consists of three cell compartments: asymmetric division in the stem cell compartment (S); division in
the amplifying compartment (A) and post-mitotic differentiation (TD). From Tudor et al 2004 (106). 
Mucosa is a part of the external barrier of the body that is constantly exposed to 
microorganisms. The integrity of the epithelium is maintained by epithelial cells 
tight junctions and a local immune system of migratory dendritic cells (DC) 
(108,109). DC´s are antigen-presenting cells that monitor changes in oral micro-
flora and communicate with T-lymphocytes of the immune system (110,111). DC´s 
express HLA-DR (Human leukocyte antigen (HLA) of the Major 
Histocompatibility Complex (MHC)) on the surface (Fig 4). Furthermore, epithelial
cells of the gastro-intestinal mucosa express HLA-DR (112,113), but the 
concentration of DCs is considerably higher in the buccal mucosa than in other 
regions (110).
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Fig 4. Normal human mucosa. Upper: Hematoxylin-eosin (H&E) stained buccal mucosa (x20). A basal 
stem cell membrane (arrow) divides submucosa and epithelia. Lower: HLA-DRB5 stained buccal 
mucosa (x20). The arrow indicate a HLA-DRB5 positive cell with dendritic expansions If present, the 
DC ś are located in the epithelia and the submucosa close to the basal membrane.
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PAPER I: A SYSTEMATIC REVIEW OF 
MOLECULAR RESPONSES TO
CANCER THERAPY IN NORMAL 
HUMAN MUCOSA    
2.1. OBJECTIVES 
The objective of this study was to provide a summary of previous studies on the 
molecular changes in normal human mucosa during cancer therapy. Our impression 
was that the current model of mucositis pathogenesis was based primarily on animal 
studies (6,80,86,89,114–116); results that were challenging to translate into a 
clinical care (117). 
2.2. METHODS
We performed a systematic review in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) (118). We 
constructed a search strategy based on a combination of medical subject headings 
(MeSH), EMTREE headings and natural language terms to search in MEDLINE 
and Ovid Embase (Appendix B). Clinical studies that described molecular changes 
in the mucosa of patients in cancer treatment at risk of developing mucositis, were 
included (119).  
2.3. PAPERS RETRIEVED FROM THE SYSTEMATIC REVIEW
Seventeen eligible full-text articles were extracted for evaluation and included in 
the analysis; nine papers describing chemotherapy affected mucosa
(6,65,67,68,120–124) (Appendix C, Table 1); and eight papers on radiated mucosa
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(75,125–131) (Appendix C, Table 2). We did not identify any papers on targeted 
therapy.
2.4. CONCLUSIONS
Only two of the studies (one paper on archived unspecific mucosa tissue and one 
paper including three AML patients) applied the GGE analysis. The studies on both 
chemotherapy and RT affected mucosa exposed that apoptosis and involvement of 
inflammatory mediators were generally present. For the chemotherapy group,
increased endothelial permeability, through tight junction disruption was involved.
For the RT group, reestablishment of the epithelial proliferation through cytokeratin 
production were indicators of early defense mechanisms. However, of the retrieved 
papers, only two studies correlated the described molecular events in the tissues to 
the clinical expression of mucositis (124,130); low expression of thymidylate 
synthase, that control DNA replication and is targeted by the chemotherapeutic 
agent 5-FU and was associated with UM (124). Among patients with various HNC
tumors the number of 27E10 positive macrophages in the submucosa was correlated 
to the grade of mucositis. However, because of the heterogeneity among the studies 
meta-analysis was not possible. 
2.5. A MODEL FOR MUCOSITIS RESEARCH IN A HUMANS
Based on our findings, we suggested conducting a number of pilot studies of similar 
nature to the ones retrieved, but with comparable designs, similar conditions and 
with a link from the molecular events in the epithelium to the clinical expression of 
mucositis. The aim of this approach was to reveal the molecular pathways 
associated with mucositis phenotypes. The design would include serial human 
mucosa biopsies and blood from patients in different cancer treatment regimens at 
risk of developing mucositis. The methodologies applied would align with the 
concept of “precision medicine” as proposed by the National Research Council 
(132,133).
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CLINICAL STUDY: MATERIALS AND 
METHODS
3.1. STUDY DESIGN
We planned to obtain three consecutive buccal biopsies and blood tests before, 
during and after therapy from each 10 patients in three different cancer treatment 
regimens: patients with multiple myeloma (MM), patients with acute myeloid 
leukemia (AML), and patients with tonsil squamous cell carcinoma (TSCC) along 
with one buccal biopsy and one blood test from 10 healthy individuals (CON). A 
plan is showed in Table 1. A detailed description of the timeline of tissue sampling
in each cohort, appear as figures in the chapters of the individual papers. 
Table 1. Study design of clinical study
Tissue 
samples
MM AML TSCC CON















Two days after 
melphalan     
(day2)
Three days after 
initiation of induction 
therapy (day2)
After one week of
RT (day7)
X
3. biopsy and 
peripheral 
blood






Twenty days after 




3.2. STRENGTHS AND LIMITATIONS
The primary limitation of this study, was the number of consecutive biopsies that 
one patient provided. However, this restriction is even more relevant using animal 
tissue, since animals are sacrificed at sampling (86,87). Second, during active 
cancer treatment, the patients are at risk of attracting complicating infections, 
especially after breaking the mucosal barrier. However, among the human studies 
retrieved in the review, no patient related complications were reported. Third, how 
did we decide when to harvest the tissues to provide relevant information? Before 
any visible macroscopic damage, the process that lead to mucositis is triggered 
immediately upon initiation of cancer therapy. This has been documented 
previously (8,134). Therefore, in order not to compromise the neutropenic patient, 
we took the second biopsy before onset of clinical mucositis and neutropenia. We 
wanted to avoid harvesting disintegrated tissue dominated by inflammatory 
mediators and to gain insight of the cellular processes that underlie the
inflammatory state. Finally, our method would provide only a snapshot of an 
ongoing process, equaling the time points that we decided; however, we did not aim 
to give the full picture and we are aware that this study is a pilot-set up that would 
potentially disclose associations that could guide future larger and more specific 
studies. 
Also relevant is a discussion on whether to use e.g., buccal swap biopsies; both 
DNA and mRNA can be extracted from this less invasive methods (135). The cells 
gained from this technique consists of desquamated keratinocytes (136) and is an
easy source of DNA extraction. However, the processes in the submucosa or 
immune related alterations will not appear when examining mRNA from these cells 
as most dendritic cells migrate to and from the epithelium (110,137). Furthermore, 
morphological information would not be available. 
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3.3. PATIENTS INCLUDED IN THE STUDY
The Committee on Health Research Ethics of Northern Denmark approved the 
clinical protocol (ref. N-20100022). We recruited patients at Aalborg University 
Hospital from September 1st 2010 to April 30th 2013. Patients were enrolled if at 
age 18 or above, if cancer treatment naïve and if they were without uncontrolled 
competitive diseases. We obtained informed written consent in accordance with the 
Declaration of Helsinki.  
3.3.1. PATIENTS WITH MULTIPLE MYELOMA 
MM is a blood cancer characterized by malignant transformation of plasma cells
(138). High-dose melphalan, supported with autologous stem cell transplantation 
(HSCT), has been the standard treatment for decades (139). Ten included patients 
with MM received a standard treatment: initial chemotherapy entailed
Cyclophosphamide 500mg/m2 i.v. day 1 and 8; Velcade 1,3 mg/m2 i.v. day 1, 4, 8, 
and 11; and Dexamethasone 20mg p.o. day 1-2, 4-5, 8-9, 11-12, repeated in 3 to 4 
series. Before harvest of stem cells, the patients were primed with 
Cyclophosphamide 2 g/m2 and treated with recombinant granulocyte stimulating 
factor (G-CSF). CD34+ hematopoietic stem cells were harvested by leukapheresis
and vital frozen in liquid nitrogen. Two days after administration of Melphalan 
(200mg/m2), stem cells were re-infused.
3.3.2. PATIENTS WITH TONSIL SQUAMOUS CELL CARCINOMA 
TSCC is a localized epithelial cancer of the tonsil. We included eight patients who 
had histology-verified TSCC and a metastasis-negative Flour-Deoxy-Glucose-
Positron-Emissions-Tomography/CT (FDG-PET/CT) scan (140). All patients 
received curative intended intensity modulated RT on six weekly fractions of 2 Gy 
according to international guidelines in the Danish Association of Head and Neck 
Cancer 2004 protocol (141,142). Dependent of the patient´s age, general health 
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status and tumor staging according to the TNM system (143), RT was supplied if 
indicated with concomitant cisplatin (40mg/m2) once a week during RT (144).  
3.3.3. PATIENTS WITH ACUTE MYELOID LEUKEMIA 
AML is a blood cell cancer of the myeloid lineage characterized by accumulation in 
the marrow of abnormal blasts that interfere with normal hematopoiesis and 
infiltrate the blood with immature blasts (138,145,146). We included six patients 
with de novo diagnosed AML. Treatment consisted basically of Cytarabine 
(100mg/m2) and Daunorubicin (60mg/m2) for 5 respectively 2 days if age 70 or 
above and  if age less than 70, for 10 respectively 3 days, supplied if indicated with 
Etoposide (100mg/m2). The treatment was adjusted to age and general health status 
according to protocol. 
3.3.4. HEALTHY INDIVIDUALS
We planned to recruit ten medically healthy, non-smoking, age and gender matched 
individuals at the Department of Maxillofacial Surgery during other planed benign 
surgery (third molar removal before orthognathic surgery). However, the majority 
of these patients did not meet the age matching criteria and recruitment expanded to 
medically healthy non-smoking age and gender matched department employees and 
friends. After informed consent, we took out one biopsy and one blood test. 
3.4. COLLECTION OF DATA AND HANDLING OF SAMPLES
3.4.1. CLINICAL DATA AND ASSESSMENT OF MUCOSITIS
All patients underwent initial evaluation including medical history and clinical 
examination at the study entry. We screened the patients for dental infections and 
these were removed prior to treatment. 
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Trained nurses recorded the OM grade daily on MM and AML during hospital stay. 
TSCC received ambulant treatment and were evaluated for OM status weekly
during RT until the acute stages of mucositis disappeared. Data of gastro-intestinal 
mucositis from the MM group was retrieved retrospectively through records. 
3.4.2. MUCOSA BIOPSIES
According to the study plan, the biopsies were harvested from the buccal mucosa.
After thorough mouth rinse with chlorhexidine and application of local anesthesia, 
0,5ml citanest (felypressin/prilocain 30 mg/ml + 0,54mikg/ml; DENTSPLY, York, 
PA, US), a lens formed 5mm biopsy was taken with a scalpel approximately 1cm 
inferior to the parotid papilla. The wound was tightly sutured with resorbable Vicryl 
4.0 (Ethicon, Summerville, NJ, US). We instructed the patients to rinse with 
chlorhexidine twice daily until removal of sutures after 10 days. The one-half of the 
biopsy was immediately embedded in RNA-later (Ambion, Thermofischer 
Scientific, Waltham, MA, US) for 24 h; then, it was frozen at -80oC. The other half 
was fixated in 10% neutral-buffered formalin, and shortly after embedded in 
paraffin and kept until further analysis. All samples were successively stored in the 
biobank until all material was secured. 
3.4.3. BLOOD SAMPLES
On the same day as the biopsy, fifteen ml of EDTA mixed venous full blood was 
taken. Mononuclear cells (MNC) were isolated using the in-house standard 
purification protocol (available at http://miltenyibiotec.com) following the 
manufactures guidelines for the Ficoll-PaqueTM (GE Healthcare, Little Chalfont,
Buckinghamshire, UK), density gradient centrifugation and a LeukosepRTube 
(Greiner Bio-One GmbH, Frickenhausen, Germany). Cells were stored in a 
freezing medium containing 10% dimethyl sulfoxide in units of 5mio, vital frozen 
at -196oC in liquid nitrogen. All samples were successively stored in the biobank 
until all material was secured. 
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3.5 DATA ANALYSES
3.5.1 GLOBAL GENE EXPRESSION ANALYSES
Genetic information stored in the DNA is translated to protein via messenger-RNA 
(mRNA) transcription, illustrated in Fig 5. The gene expression technology offers a 
genome wide approach to this central cellular process (147). We performed the
analysis at the mRNA level, to provide a print of transcriptional activity in the 
tissues (phenotype). 
Fig 5. DNA transcription and translation. Information stored in the DNA is translated to protein via 
mRNA transcription. http://www.nature.com/scitable/topicpage/translation-dna-to-mrna-to-protein-393.
We used the Affymetrix GeneChip Human Exon 1.0 ST Arrays with approximately 
4 probes per exon and 40 probes per gene.  With more than 1.4 million probe sets, 
analysis of both gene expression and alternative splicing was available. The 
workflow is shown in Fig 6. The mucosa samples were homogenized using TRIzolR
Reagent (Invitrogen, Paisley, UK) and total RNA was isolated using mirVanaTM 
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miRNA Isolation Kit (AmbionR/Invitrogen, Paisley, UK) according to manufactures 
protocol (Life Technologies Corporation). RNA amplification was performed on TP 
Basic Thermocycler real time PCR instrument (BiometraR) following standard 
reaction conditions as described in the manufacturers manual “The AmbionRWT 
Expression Kit” (Applied BiosystemsR) starting out with 100ng total RNA. The 
Quality of RNA product vas evaluated by NanoDrop and Bioanalyzer using Agilent 
RNA 6000 Nano Kit (Agilent TechnologiesR). The samples were prepared for 
hybridization to Affymetrix GeneChip Human Exon 1.0 ST Arrays using 
Affymetrix GeneChip WT Terminal Labeling and Controls Kit (P/N 901524), 
following the manufacturer’s instructions. CEL-files were generated by Affymetrix 
GeneChip Command Console Software. A similar procedure was applied on MNC 
from blood samples from the MM and TSCC group. 
Fig 6. The workflow of gene expression analysis. 
3.5.2 IMMUNOHISTOCHEMISTRY
The formalin fixed, paraffin embedded (FFPE) tissue-blocs were cut at 4μm and 
mounted on glass sheets, dried for 24 hours and hereafter kept frozen (-20 oC) until 
the dying procedure. One slice of all tissue samples were H&E stained for control.
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Based on the results from the gene expression analysis, antibodies were acquired 
for immunohistochemical stain. After evaluation using an in-house optimized 
protocol, tissues were stained accordingly. The specimens were then scanned in a 
Hamamatsu Nanozoomer slide scanner and analyzed in the NDP viewer software. 
3.6 STATISTICAL ANALYSES
All statistical analyses were performed with R (148) version 3.2.0 and 
Bioconductor packages (149).
3.6.1 ESTIMATION OF POWER SIZE
To detect genes that varied more than two-fold between test points with a false 
discovery rate (FDR) of less than 0.05% and a power of 90%, we applied the 
method described by Lee and Whitmore (150), implemented in the R-package, size-
power (Qui 2008) (151). Ten patients in each group was calculated to be sufficient 
for detecting major significant differences. 
3.6.2 DATA PROCESSING
The Affymetrix Expression Console produced CEL files that were preprocessed and 
summarized at the gene level using the RMA algorithm with the Bioconductor 
package affy using custom CDF-files (152). The preprocessing of the CEL files 
resulted in the expression levels of 38,830 genes for each array and was annotated 
with Ensembl gene identifiers (ENSG identifiers). Patient CON09 was included in 
the normalizations of the gene expression data in the MM group, but excluded in 
the statistical analysis because he suffered from the autoimmune disease psoriasis. 
CON09 was excluded completely from the TSCC and the AML cohorts. 
3.6.3 DETECTION OF DIFFERENTIAL EXPRESSION
With patient ID as a cluster variable, we used the linear model for microarray data 
(limma package in R), a mixed linear model, and an empirical Bayes approach to 
test for significant differences in gene expression levels between day2 and day0, 
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and between day21 and day0 (153). We performed an unpaired test with the limma 
package to test for significant differences in gene expression between patients on 
day0 and controls. We adjusted the p-values for false discovery rates and they were 
controlled with the method described by Benjamini-Hochberg (154), for each test. 
We considered adjusted p-values below 0.05 as significant. According to their 
mucositis experience, the patients were divided into UM or NM. 
We applied the Mann-Whitney test to test for the relationship between mucositis 
severity and duration of neutropenia, leukopenia, and thrombocytopenia in the MM 
group. We also used the Mann-Whitney test to evaluate differences between groups 
in the numbers of in-hospital days and years of progression free survival (PFS) in 
the MM and AML group. 
The GGE data set of all nine CON samples and eight TSCC samples was divided 
into subsets by gene biotypes: protein coding, pseudogene, miRNA, rRNA, 
snoRNA, snRNA, linRNA, and antisense transcript. Each dataset was subjected to 
hierarchical clustering using Pearson correlation as a distance measure and average
linkage as the algorithm method. Using adjusted p-values from the pairwise test, all 
genes were ranked by the degree of differential expression (DDE) calculated as: 
DDE = -log10 (P-value) * (ABS(FC)/FC), where the fold change (FC) in gene 
expression between the groups was compared. This approach leaves highly up-
regulated genes at the top of the ranked list and downregulated genes at the bottom. 
Each ranked list was subjected to gene set enrichment analysis using the GSEA 
software and Reactome pathways as gene sets (155–157). Gene sets with an FDR < 
0.05 were considered enriched. 
For the detection of alternative spliced genes the CEL-files produced by the 
Affymetrix Expression Console were imported as full exon import file into and 
analyzed by Partek Genomic Suite software following manufacturers default 
workflow (Partek Incorporated, St. Louis, USA). 
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PAPER II: MOLECULAR 
CHARACTERISTICS OF HIGH-DOSE 
MELPHALAN ASSOCIATED 
MUCOSITIS IN PATIENTS WITH 
MULTIPLE MYELOMA: A GENE 
EXPRESSION STUDY ON HUMAN 
MUCOSA
Below, Fig 7 outline a detailed study plan for the MM group. 
Fig 7. Study design for the MM cohort. Tissue was collected before Melphalan, 2 days after melphalan 
at stem cell reinfusion and at an outpatient control visit 21 days after melphalan. Patients without 
progressive disease were recruited and clinical data was collected after the induction treatment. Tissues 
were collected and stored successively in our biobank and analyzed collectively at the same laboratory. 
In this study of patients with MM receiving melphalan, we identified the up- or 
down-regulation of genes belonging to pathways that were previously recognized as 
inducers of mucositis, e.g., apoptotic, inflammatory, and DNA repair genes.  
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However, these changes were not associated with the severity of clinical mucositis
(Fig 8). 
Furthermore, we identified both inducers and inhibitors of apoptosis. Melphalan
induces oxidative stress and upregulates apoptosis-related genes (78,158). In our 
material, EDA2R, an inducer of apoptosis, was up-regulated. EDA2R encodes a 
TNF-receptor that mediates the NF-κB and JNK pathways resulting in caspase
induced apoptosis (75,123,159,160). However, INPP5D, which encodes a 
membrane protein that negatively regulates JNK signaling, and limits Fas-FasL-
induced apoptosis in T-lymphocytes found at mucosal surfaces was also up-
regulated (161). Furthermore, we found alteration of five genes involved in 
suppression of the p53 apoptotic pathway: MDM2, CUL9, E2F7, and TIGAR (up-
regulated) and SERRPINB10 (downregulated). MDM2 encodes a protein ligase that 
inhibits p53-mediated cell cycle arrest and apoptosis (162). Several studies have 
reported p53 as an inducer of mucositis (67–69). However, the genes related to
apoptosis in our study, including EDA2R, did not correlate to the level of clinical 
mucositis and was also up-regulated in patients who did not develop clinical 
mucositis. A similar pattern was seen in the expression of POLH, a gene that 
encodes a specialized polymerase that accurately replicates damaged DNA. 
TREM2 and LAMP3 (up-regulated) encodes membrane proteins expressed on DC´s 
and involved in T-cell activation and inflammation (163,164). The protein encoded 
by TREM2, can bind and phagocytose yeast species, Gram-positive and Gram-
negative bacteria (165,166). Additional, DC´s secrete cytokines (e.g., IL-12 and 
type I interferon) in response to antigen exposure. IL-12 mobilizes natural killer 
(NK) cells. Also, we saw NCR3LG1 up-regulated, a gene encoding a ligand 
triggering NK cells (167). Thinning of the epithelium, causing exposure of the 
microbiota in combination with changes in its composition and concentration was 
previously recognized to contribute to the development of mucositis (19,168). Our 
results confirmed this; however, we did not find an association to mucositis 
severity.
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The genes ABCA12 and CEL were up-regulated on day2. ABCA12 encodes a 
membrane transporter protein primarily involved in the keratinocyte lipid-barrier 
that maintains homeostasis in the epidermis (169). ABCA12 has not previously been 
associated with mucositis, but ABCA12 may be a similar barrier protection. CEL
encodes a lipase with multiple functions in lipid metabolism, and is expressed in 
macrophages (170). The expression of both these genes was also without relation to 
the clinical expression of clinical mucositis
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Fig 8. Dot plot of gene expression before, day 2, and day 21 after melphalan. Red = UM; green = NM; 
blue = CON. First row: genes associated to apoptosis: EDA2R, MDM2, and INPP5D. Second row left: 
genes affecting DNA repair/transcription, POLH and HIST1H1A. Second row right and third row left: 
genes related to inflammation, TREM2 and NCR3LG. Third row right: genes related to metabolism: 
ABCA12 and CA2. Mucositis severity was not correlated to the alterations of these genes.
We identified potential predictive biomarkers for mucositis severity: HLA-DRB1 
and HLA-DRB5. These genes belong to the MHC Class II family members and 
encode a surface protein located on specialized antigen presenting cells, e.g., 
Langerhans cells (112,171–173). Both genes were up-regulated in NM compared to 
UM and CON (Fig 9). 
APP 40
Fig 9. Genes differentially expressed according to mucositis grade. Left: HLA-DRB1 and right: HLA-
DRB5 at baseline (day0), two days (day2), and 21 days (day21) following high-dose melphalan. The 
level of expression of these genes did not vary upon treatment. Red = UM; green = NM; blue = CON. 
HLA-DRB1 was expressed in two splice variants: NM_002124 (UM and CON) 
containing six exons and NM_001243965 (NM and CON09) containing seven 
exons (Fig 10).  
Fig 10. Alternative splicing analysis of HLA-DRB1. HLA-DRB1 was expressed in two splice variants: 
NM_002124 (six exons), and NM_001243965 (seven exons). NM and CON09 expressed the longer 
variant.
We confirmed the result from the gene expression analysis with 
immunohistochemical stain for HLA-DRB5 (Fig 11). Generally, if present, the 
HLA-DRB5 positive cells were localized in the lower part of the epithelium, near 
the basal membrane, around the papillae, and in the upper part of the submucosa. 
The morphology of the positively stained cells was similar to DC´s.  
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Fig 11. Immunohistochemical analysis for HLA-DRB5 of the oral buccal mucosa (20 magnification)
from patients with multiple myeloma. (a) High HLA-DRB5 expression in MM01 with mild mucositis. (b) 
Low HLA-DRB5 expression in MM18 with severe mucositis. The square highlight the morphology of one 
of the HLA-DRB5 stained cells: noticeable cellular extensions similar to those observed in dendritic 
cells. 
CON09 expressed the same elevated levels of HLA-DRB1 and HLA-DRB5 as the 
NM. This patient suffered from psoriasis. Psoriasis is a skin disease of auto-immune 
origin, characterized by reduced apoptosis; polymorphisms in HLA-related genes 
were previously reported (177). One study described that these patients are 70% 
less prone to develop mucositis (8,49). CON09 also expressed ABCA12 at different 
level together with NM in contrast to UM and the other CON´s. This was also 
found in a previous gene expression study on psoriasis patients (178). 
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PAPER III: ORAL MUCOSA TISSUE 
GENE EXPRESSION PROFILING 
BEFORE, DURING, AND AFTER 
RADIATION THERAPY FOR TONSIL 
SQUAMOUS CELL CARCINOMA
Below the study design for the TSCC cohort is shown (Figure 12). 
Fig 12. Study design for the TSCC cohort. Tissue was collected before RT, after one week of RT and 20 
days after the last RT session. Clinical data was collected at entrance to the study. Tissues were stored 
successively in our biobank and subsequently analyzed collectively at the same laboratory. 
Upon seven days of RT, we identified genes related to apoptosis that were up-
regulated in patients with TSCC, similar to the response seen in melphalan treated 
patients with MM: EDA2R that encodes a TNF receptor activating the NF-κB and 
jun-N-terminal (JNK) apoptotic pathways, and MDM2 encoding a ligase that 
inhibits p53-mediated apoptosis (162). Indicating additional DNA damage, six 
members of the histone cluster families (e.g., HIST1H3B) were downregulated. 
Histones are basic nuclear proteins responsible for nucleosome structure. A
previous study described histone down-regulation in response to RT in cell lines 
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(174). POLH was up-regulated like in the MM group indicating DNA repair. 
Transcriptional activity was also affected; KRT16 (up-regulated) encodes keratin16, 
an epithelial filament protein that is responsible for cell structure that is expressed 
in early differentiated epithelial cells (106,125,175). Also, keratin16 may 
participate in innate immunity regulation in response to mucosal trauma (126,175).
Contrary, MKI67 encoding the proliferation marker Ki-67 was downregulated. In a 
previous study Ki-67 was up-regulated two weeks after radiation (126). Dot-plots of 
selected altered genes is shown in Fig 13. In long-term in response to RT, we found 
alterations of SCIN (down–regulated) that encodes a protein with regulatory 
functions in exocytosis (176). We expected to find this gene expressed in the 
salivary glands, however immunohistochemical stain revealed that scinderin was 
expressed in the epithelial cells (Fig 14). Finally, MIR31HG, a long non-coding 
snRNA with unknown function, was only long-term up-regulated in patients 
receiving cisplatin. None of these alterations were correlated to mucositis severity
(Fig 13). 
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Fig 13. Gene expression before (day0), after 7 days of RT (day7), and 21 days (day21) following the 
total RT dosage administrated. Red = UM; green = NM; blue = CON. First row: genes associated with
apoptosis: EDA2R and MDM2. Second row: genes affecting DNA repair/transcription, HIST1H3B and 
POLH. Third row: genes altered long-term: IL1R1 and SCIN. These genes were independently expressed 
of clinical mucositis.
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Fig 14. Immunohistochemical analysis of buccal oral mucosa (x15 magnification) stained for scinderin
shows a staining of the epithelial cells. (a) High scinderin expression in the mucosa of patient CON05. 
(b) Low scinderin expression in the mucosa of patient TSCC07, 20 days after the last RT session. 
Although not statistically significant, LY6G6C (lymphocyte antigen 6 complex, 
locus G6C) was up-regulated (x3.78; P=0.0995) in patients with NM compared to
UM before treatment (Fig 15). LY6G6C belongs to a cluster of leukocyte antigen-6 
genes of the MHC Class III, encoding a cell signaling surface protein (177). 
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Fig 15. LY6G6C expression in the mucosa of patients with TSCC receiving RT at baseline (day0), after 
seven days of RT (day7), and 21 days (day21) after the last RT session. Red = UM; green = NM; blue = 
CON. Patients with NM encircled at baseline. 
Before RT application, we found altered genes in the mucosa of TSCC compared to 
CON: LIFR (leukemia inhibitor factor alpha), PDGFRA (platelet-derived growth 
factor receptor alpha), and SPARCL (secreted protein acidic and cysteine rich) (Fig
16).
Fig 16. Dot plots of LIFR, PDGRF, and SPARCL expression in the mucosa of patients with TSCC 
receiving RT at baseline (day0), after seven days of RT (day7), and 20 days (day20) after the last RT 
session. Red = UM; green = NM; blue = CON. All three genes are expressed unaffected of RT. 
These genes were independently expressed of alcohol consumption, smoking 
habits, and p16 overexpression in the tumor. The gene LIFR encodes a 
transmembrane receptor protein of the type 1 cytokine receptor family, which is 
involved in cellular differentiation, proliferation, and survival and acts as an 
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inhibitor of the p53 apoptotic pathway. Low expression was identified as both a 
suppressor and a promotor of carcinogenesis (178). PDGFR encodes a cell-surface 
tyrosine kinase receptor for the platelet-derived growth factor family members that 
activates cell migration and chemotaxis pathways in wound healing (179); certain 
mutations in the PDGFRA gene was identified in cancer progress (180). SPARCL is 
involved in extracellular matrix synthesis and was downregulated in a number 
human cancer types (181). It remains unclear why these genes connected to 
carcinogenesis were expressed in clinically normal appearing oral mucosa at a 
distance from the tonsil squamous cell carcinoma.
In the blood, we also identified a gene signature before any treatment was applied. 
Fig 17 shows two of 29 altered genes, RNU6-620P (downregulated; FC=11.8; 
P=5.80e-80) and RNU6-622P (up-regulated; FC=7.3; P=8.62e-05) compared to 
normal controls. This was a finding without association to mucositis, however 
interesting, and a potential candidate for cancer diagnosis. 
Fig 17. Dot plots of RNU6-620Pand RNU6-622P expression in blood of patients with TSCC receiving 
RT at baseline (day0), after seven days of RT (day7), and 20 days (day20) after the last RT session. Red 
= UM; green = NM; blue = CON. Both genes are expressed independently of RT. 
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PAPER IV: MOLECULAR 
CHARACTERIZATION OF MUCOSA IN 
PATIENTS WITH ACUTE MYELOID 
LEUKEMIA
Below Fig 18 shows a detailed study plan for the AML group. 
Fig 18. A detailed description of the study design for the AML cohort. The first biopsy was collected 
before initiating induction therapy (Day0); the second after 3-5 days of chemotherapy (Day3); and the 
third biopsy was harvested at an out-patient control visit 19-41 days after the last chemotherapy session
(Day27), just before initiating the second induction treatment. Tissues were stored successively in our 
biobank and subsequently analyzed collectively in our laboratory. 
The clinical characteristics and demographics of the patients with AML is shown in 
Table 2 and data during treatment in Table 3. Clinical mucositis was registered with 
an average score of 1.3 (range 0-3); two patients experienced UM. One AML
responded completely to the cancer treatment, while five relapsed. Of these, only 
one survived. Overall survival was 2.7 years (range 1.5-4.3); for the UM group 3.9
years (range 3.4-4.3) and for the NM group 1.9 (range 1.5-4.2). Event free survival 
was 1.1 (range 0-4.0) for the UM group 2.9 (1.5-4.3) and for the NM group 0.3 
(range 0-1). 
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Table 2. Patients characteristics and demography at entrance to the study
Patient Age Gender ECOGa BMIb Smoc Alcd FABe Treatment
AML01 58 m 1 29.3 0 0 M6 Cy 10 days
Da 3 times
Mylo
AML02 69 m 1 26.8 1 0 M2 Cy 8 days
Da 3 times
Etop 4 days
AML04 59 f 1 21.4 0 0 M5 Cy 8 days
Da 3 times
Etop 4 days 
Mylo
AML05 58 f 1 23.8 0 0 M4 Cy 10 days
Da 3 times
Etop 5 days
AML07 75 f 1 27.1 0 0 M2 Cy 5 days
Da 2 times
AML09 74 m 2 23.9 1 0 M4 Cy 5 days
Da 2 times
Abbreviations: a=Eastern Cooperative Oncology Group performance status; b=body mass index; c=smoking more 
than 10 cigarettes per day; d=drinking more than 21 units of alcohol weekly; e=FAB: French-American-British 
subtype classification; Cy=Cytarabine 100mg/m2 twice daily; Da=Daunorubicin 50mg/m2 once every second day; 
Etop= Etoposide 100mg/m2 once daily. Mylo= Mylotarg 3mg/m2 once; 











Patients with ulcerative mucositis
AML01 3 3 41 MDS 
AML
3.4 1.5 dead
AML02 3 4 19 no 4.3 4.3 CR
Patients with  no/mild mucositis
AML04 0 4 No third 
biopsy
AML 4.2 1.0 relapse
AML05 0 3 22 AML 1.5 0 dead
AML07 1 3 27 AML 1.5 0 dead
AML09 1 5 27 AML 1.5 0 dead
Abbreviations: a= Mucositis estimated according to WHO (REF Quinn); b=number of days from initiation of 
induction therapy to second biopsy; c= number of days from end of first induction therapy to third biopsy. The 
third biopsy was secured immediately before initiation of second induction treatment. d=overall survival estimated 
as years from diagnosis/enrolment into study until death; c=event-free survival estimated as years from 
diagnosis/enrolment into study to disease progression/relapse. CR=complete response
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In response to treatment, we identified a total of four genes differently expressed
(Appendix F, Fig 19): two genes of the histone cluster family, HIST1H1A and 
HIST1H2BM, were downregulated, POLH encoding a transcriptional DNA directed 
polymerase and NOTCH1 encoding a membrane protein responsible for 
intercellular signaling that regulates interactions between physically adjacent cells, 
were up-regulated. 
Fig 19 Gene expression before (Day0), after 3-4 days of chemotherapy (Day3), and before initiation of 
second induction therapy (Day27). Red = UM; green = NM; blue = CON. First row: genes of the 
histone family: HIST1H1A and HIST1H2BMB. Second row: POLH and NOTCH1. Although not
statistically significant, there was a tendency towards upregulation of POLH and NOTCH1 in response 
to treatment among the patients that did not develop mucositis, see arrows. These genes were also 
differently expressed in the MM and TSCC group, but not with the same distinction. 
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Before treatment was initiated two genes were differently expressed in the mucosa,
LINC01975 and RNU6-996P (up-regulated) (Fig 20). 
Fig 20. Gene expression of LINC01975 (left) and RNU6-996P (right) before (Day0), after 3-4 days of 
chemotherapy (Day3), and before initiation of the second induction therapy (Day27). Red = UM; green 




Initially, mucositis has been assumed to be the result of chemotherapy and RT
causing apoptotic and necrotic changes in the cells of the epithelial basal stem cell 
layer, being more sensitive to genotoxic injury due to a high turnover rate 
(106,182). Several studies have pointed to initial apoptosis but also to inflammatory 
mediators as the key inducers of mucositis in animal models (6,70,74,91,183,184), 
but also in humans (75,89,116,160,185). Among these, TNF-α, the interleukins IL-
1β, IL-6, IL-10, the transforming growth factor beta (TGF-β), p53, NF-κB and 
MMP´s, but with conflicting results. Because of the central role for inflammation, 
many anti-inflammatory medications has been tried and worked well in the animal 
models, but did not reduce mucositis; e.g., Pentoxifylline and Thalidomide (TNF-α 
inhibitors), synthetic prostaglandin and Misoprostol (186–189), or Celecoxib and 
Infliximab (selective inflammatory inhibitors) (190,191). This leads to discussion
weather to use animal models to study mucositis regarding similarities and 
differences between human and mouse inflammatory reactions. Although debated, 
some studies have shown a poor correlation, mainly on B-cell receptor signaling, 
macrophage and monocyte function, and the expression over time of the alpha 
chain of the HLA-DR class II (192). In addition, in more of the animal studies the 
mucosa was scratched to provoke oral mucositis to appear, which may have 
distorted the results (193–195). Our model of harvesting human mucosa tissue for 
analysis proved feasible and we identified alterations in apoptotic, DNA damage 
and repair genes changes in the mucosa in response to cancer treatment in all three 
cohorts. However the treatment induced changes did not correlate to the level of 
clinical mucositis. 
There may be a complexity of factors involved in pathogenesis of mucositis
involving both host response, microbiome, treatment modality, type of disease and 
patient phenotype. Based on identification of both disease and treatment specific 
differences in gene expression in our study, we propose that the mechanisms 
APP 53
underlying mucositis must be studied using human tissues (192,196). This 
statement is emphasized by the identification of two a potential prognostic 
biomarkers, in both cases genes encoding cell surface proteins involved in immune 
signaling (HLA-DRB1, HLA-DRB5, and LY6G6C). This finding indicate that 
protective immunity is a central issue in mucositis pathogenesis, but dependent of 
the patient phenotype. Moreover, among patients with AML upregulation of the 
two genes POLH and NOTCH1 seem to protect against severe mucositis. 
Additionally, we merged gene expression data from all three cohorts (MM, TSCC, 
and AML) and performed a principal components analysis (Fig 20). Patients cluster 
according to disease indicating that disease is foremost contributor to the variation 
in gene expression of the mucosa samples and not mucositis grade.
The results in these three pilot studies, leads us conclude that the model of 
consecutive human biopsies is feasible to design prospective clinical validation 
trials, including sufficient numbers of patients to characterize molecular mucositis 
and identify disease specific predictive mucosa gene signatures (MUGS).
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Fig 20. PCA analysis of the gene expression of mucosa biopsies before, during and after treatment from 
the three cohorts, MM, TSCC, and AML. Red = MM; Green = AML; Blue = TSCC; Black = CON.
Patients do not cluster according to mucositis grade, but cluster according to disease. 
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PERSPECTIVE AND FUTURE 
RESEARCH
This pilot study has generated new hypotheses to investigate. Most importantly, that 
the pretreatment phenotype of the local immune system in the mucosa among the 
MM and the TSCC cohort distinguish patients according to mucositis grade. Since 
such potential predictive genetic markers were present in the mucosa tissue before 
treatment in MM and TSCC, a prospective validation trial must involve more 
patients having only one biopsy taken prior to treatment, which would simplify the 
study. Furthermore, this approach may allow us to expand the model to study other 
disease categories, e.g., patients with malignant lymphoma, all patients receiving 
HSCT or all patients with various head and neck cancers instead of only TSCC. The 
perspective is, that if we confirm the importance of these biomarkers, we may be 
able to stratify patients before treatment in the future and adjust treatment including 
supportive care accordingly.
Finally, we have issued a request for a patent on a potential method to diagnose 
TSCC in the blood using RNU6-620P and RNU6-622P as biomarkers (Appendix 
G). We plan a study recruiting all patients referred to the ENT department on 
suspicion on HNC in parallel with developing a method using PCR instead of GGE 
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APPENDIX A: CLINICAL MONITORING OF MUCOSITIS
Table 1: WHO oral mucositis assessments scale
grade 0 no patient discomfort or erythema only
grade 1 soreness present with or without erythema
grade 2 ulcers present but able to eat solids food
grade 3 ulcers present only able to take liquid diet 
grade 4 ulcers present alimentation not possible
Abbreviations: WHO=World health Organization 
Table 2: CTCAE Gastrointestinal disorders
Grade 1 Increase of <4 stools per day over baseline
Grade 2 Increase of 4-6 stools per day over baseline
Grade 3 Increase of >=7 stools per day over baseline, incontinence
Grade 4 Life threatening, urgent intervention indicated
Grade 5 Death
Abbreviations: CTCAE = Common Terminology Criteria for Adverse 
Events of The National Cancer Institute (NCI) of the National Institutes 
of Health (NIH) of gastrointestinal disorders. 
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APPENDIX B: LITERATURE SEARCH 
Algorithm for electronic search in MEDLINE, chemotherapy and targeted therapy
1 Mucositis/ or exp stomatitis/ 16311
2 (mucosa adj3 inflammation*).ti,ab. 816
3 (mucositis or stomatitis).ti,ab. 21735
4 1 or 2 or 3 33127
5 exp Gene Expression/ or exp Gene Expression Profiling/ 477129
6 (expression* or profiling or transcript* or analys* or analyz*).ti,ab. 5886084
7 exp Biomarkers/ 787048
8 biomarker*.ti,ab. 162860




11 exp Antineoplastic Agents/ 952924
12 Antineoplastic Combined Chemotherapy Protocols/ 125973
13 Consolidation Chemotherapy/ 308
14 Maintenance Chemotherapy/ 1024
15 combined modality therapy/ or chemoradiotherapy/ or chemotherapy, adjuvant/ or 
neoadjuvant therapy/ or photochemotherapy/ or Molecular Targeted Therapy/
234159
16 (chemotherap* or molecular’ target* therap*).ti,ab. 345042
17 or/11-16 1285457
18 exp Neoplasms/ 2962050
19 (neomplasm* or cancer).ti,ab. 1350009
20 or/18-19 3291994
21 4 and 10 and 17 and 20 2113
22 21 not (exp animals/ not humans.sh.) 2031
23 limit 22 to "review" 178
24 22 not 23 1853
Algorithm for electronic search in Ovid Embase, chemotherapy and targeted therapy
1 mucosa inflammation/ 28686
2 exp stomatitis/ 44129
3 (stomatitis or mucositis).ti,ab,kw. 28421
4 (mucosa adj3 inflammation*).ti,ab,kw. 1262
5 or/1-4 78879
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6 exp gene expression/ 1345969
7 exp genetic transcription/ 864515
8 exp genetic procedures/ 1556727
9 (gene* adj3 (expression* or profiling or transcript*)).ti,ab,kw. 594742
10 biological marker/ or exp cell marker/ 288243
11 biomarker*.ti,ab,kw. 261887




14 exp antineoplastic agent/ or molecularly targeted therapy/ 1891297
15 exp chemotherapy/ 590012
16 (chemotherap* or molecular* target* therap*).ti,ab,kw. 514794
17 or/14-16 2153387
18 exp neoplasm/ 4007936
19 (cancer or neoplasm*).ti,ab,kw. 2051085
20 18 or 19 4267080
21 5 and 13 and 17 and 20 2975
22 21 not ((exp animal/ or nonhuman/) not exp human/) 2882
23 limit 22 to "review" 937
24 22 not 23 1945
Algorithm for electronic search in MEDLINE, radiotherapy
1 Mucositis/ or exp stomatitis/ 16536
2 (mucosa adj3 inflammation*).mp. 835
3 (mucositis or stomatitis).mp 30793
4 1 or 2 or 3 36350
5 exp Gene Expression/ or exp Gene Expression Profiling/ 549370
6 (expression* or profiling or transcript* or analys* or analyz*).mp 7191673
7 exp Biomarkers/ 819103
8 biomarker*.mp. 439680




11 exp Radiotherapy/ 167199
12 exp Radiation/ 453417
13 Radiation Injuries/ 32276
14 (radiotherap* or radiation* or irradiation).mp. 684168
15 or/11-14 902060
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16 exp Neoplasms/ 3093726
17 (neoplasm* or cancer).mp. 2972806
18 16 or 17 3486594
19 4 and 10 and 15 and 18 1087
20 19 not (exp animals/ not humans.sh.) 1040
21 limit 20 to "review" 93
22 20 not 21 947
Algorithm for electronic search in Ovid Embase, radiotherapy
1 exp stomatitis/ 43052
2 mucosa inflammation/ 27972
3 (stomatitis or mucositis).ti,ab,kw. 27806
4 (mucosa adj3 inflammation*).ti,ab,kw. 1245
5 or/1-4 77064
6 exp gene expression/ 1271586
7 exp genetic transcription/ 819928
8 exp genetic procedures/ 1514592
9 (expression* or profiling or transcript* or analys' or analyz*).ti,ab,kw. 3723339
10 biological marker/ or exp cell marker/ 275886
11 biomarker*.ti,ab,kw. 246805




14 exp radiotherapy/ 442944
15 exp radiation/ 621562
16 exp radiation injury/ 62192
17 (radiotherap* or radiation* or irradiation).ti,ab,kw. 650962
18 or/14-17 1191939
19 5 and 13 and 18 1887
20 exp neoplasm/ 3905765
21 (neomplasm* or cancer).ti,ab,kw. 1814752
22 20 or 21 4142376
23 19 and 22 1631
24 23 not ((exp animal/ or nonhuman/) not exp human/) 1593
25 limit 24 to "review" 298
26 23 not 25 1333
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APPENDIX C: PAPERS RETRIEVED
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APPENDIX D: GENE LIST MM
Gene 
symbol
FC p-value adjusted       
p-value 
Qualified GO term Function




























1.05e-09 E2F transcription factor 7 Apoptosis
NCR3LG1 2.70 1.14e-
10
1.94e-07 Natural killer cell cytotoxicity 




















1.24e-10 Polymerase; DNA directed Transcription
ARNTL 2.40 2.65e-
06















3,58e-11 Carboxyl ester lipase Metabolism
CA2 2.57 9.99e-
10
1.18e-06 Carbonic anhydrase II Metabolism
SLC39A6 2.53 1.16e-
10
2.00e-07 Solute carrier family 39 Metabolism
SPATA18 2.19 2.16e-
12
6.98e-09 Spermatogenesis associated 18 Metabolism
P3H2 2.10 2.28e-
09
2.46e-06 Prolyl 3-Hydroxylase 2 Metabolism
F3 2.09 0.00037 0.027 Coagulation Factor III Metabolism
GLS2 2.01 4.79e-
14
3.1e10 Glutaminase 2 Metabolism
WDR63 2.84 7.16e-
11
1.35e-07 WD Repeat Domain 63 Unknown
RN7SL519P 2.05 0.00061 0.037 Pseudogene Unknown 
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0.00201 Nuclear Receptor Subfamily 1, 




0.00015 0.0142 Nuclear Receptor Subfamily 1, 























































APPENDIX E: GENE LIST TSCC
GENES ALTERED IN MUCOSA
Gene symbol FC p-value
adj. p-
value
Qualified Gene Ontology term Function
Baseline 








































Mucosa – up-regulated genes at baseline versus healthy controls
RN7SL783P 2.54 0.00010 0.031 pseudogene
Unknown 
function










After seven days of radiotherapy 
Gene symbol FC p-value
adj. p-
value
Qualified Gene Ontology term Function




































2.58e-06 0.0016 Marker Of Proliferation Ki-67 Transcription
Mucosa – up-regulated genes on day7 versus baseline
WDR63 2.67 1.09e-10 1.1e-06 WD Repeat Domain 63 Unknown
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MDM2 2.29 6.77e-11 4.26e-11
MDM2 oncogene, E3 ubiquitin 
protein ligase
Apoptosis
EDA2R 2.26 8.38e-11 1.0e-06 Ectodysplasin A2 receptor Apoptosis
POLH 2.17 3.22e-10 1.81e-06 Polymerase; DNA directed Transcription
KRT16 2.15 0.00058 0.052 Keratin 16 Cell structure
Three weeks after RT cessation
Gene symbol FC p-value
adj. p-
value
Qualified Gene Ontology term Function













































Interleukin 1 Receptor Type 2; 
cytokine receptor of the interleukin 1 
receptor family
Immune response
Mucosa – up-regulated genes on day 21 versus baseline 
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MIR31HG 5.30 5.71e-05 0.035 Non-coding microRNA no 3
Non-coding mi-
RNA
CCAT1 3.08 1.08e-05 0.018 Colon Cancer Associated Transcript 1 Non-coding RNA
PTPRZ1 2.93 0.000103 0.047
Protein Tyrosine Phosphatase, 
Receptor Type Z1
Transcription
Mucosa - downregulated genes in patients with mucositis vs. no mucositis at baseline
Gene symbol FC p-value
adj. p-
value








GENES ALTERED IN BLOOD CELLS
Gene symbol FC p-value
adj. p-
value
Qualified Gene Ontology term Function





































ArfGAP With GTPase Domain, 













6.81e-06 0.0040 Ornithine decarboxylase antienzyme 1
























RNA, 7SL, cytoplasmic 432, 
pseudogene
pseudogene
Blood up-regulated genes at baseline versus healthy controls
RNU6-622P 7.30 7.74e-09 8.62e-05
RNA, U6 Small Nuclear 622, 
Pseudogene
pseudogene




SSU72P8 3.44 1.07e-07 0.0014
RNA Polymerase II CTD Phosphatase 
Homolog, Pseudogene 8
pseudogene
RNU6-919P 3.37 1.06e-05 0.0051
RNA, U6 Small Nuclear 919, 
Pseudogene
pseudogene
RPS6P15 3.01 2.82e-06 0.0024 Ribosomal Protein S6 Pseudogene 15 pseudogene
RN7SL748P 2.44 1.59e-05 0.0061
RNA, 7SL, Cytoplasmic 748, 
Pseudogene
pseudogene
RPL10P4 2.33 2.88e-07 0.00051 Ribosomal Protein L10 Pseudogene 4 pseudogene
RPL21P133 2.32 6.39e-07 0.0010




RN7SL290P 2.22 1.06e-05 0.0051
RNA, 7SL, Cytoplasmic 290, 
Pseudogene
pseudogene
OR5M4P 2.21 4.97e-05 0.011
Olfactory Receptor Family 5 
Subfamily M Member 4 Pseudogene
pseudogene
RNU6-151P 2.19 1.58e-07 0.00036
RNA, U6 Small Nuclear 151, 
Pseudogene
pseudogene
RNU6-135P 2.19 1.29e-07 0.00034
RNA, U6 Small Nuclear 135, 
Pseudogene
pseudogene
RNA5SP116 2.18 0.00085 0.046 RNA, 5S Ribosomal Pseudogene 116 pseudogene
NUTM2D 2.13 0.00016 0.021 NUT family member 2D unknown
RNA5SP54 2.06 8.49e-08 0.00030 RNA, 5S Ribosomal Pseudogene 54 pseudogene
RN7SL865P 2.05 0.00074 0.043
RNA, 7SL, Cytoplasmic 865, 
Pseudogene
pseudogene
RPS29P8 2.00 8.69e-07 0.0012 Ribosomal Protein S29 Pseudogene 8 pseudogene
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APPENDIX F: GENE LIST AML
Table 3 Genes altered more than 1.5 fold (P < 0.05) in the buccal mucosa of patients with AML
Gene symbol FC p-value adj. p-
value
Qualified GO term Function
Baseline versus healthy controls
RNU6-996P 2,04 2,28E-
07
0,0067 RNA, U6 Small Nuclear 996, 
Pseudogene
unknown
LINC01975 1.66 2.33e-06 0.030 Long Intergenic Non-Protein 
Coding RNA 1975
unknown
Day 2 versus baseline
HIST1H1A -3.20 8.08e-10 3.18e-05 Histone Cluster 1, H1a transcription
HIST1H2BM -2.83 2.48e-06 0.024 Histone Cluster 1, H2BM transcription
POLH 2.18 1.97e-06 0.024 Polymerase; DNA directed transcription
NOTCH1 1.85 2.04e-06 0.024 NOTCH 1 cell signaling
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Statement of Clinical Relevance: Clinical tools for pretreatment identification of patients likely to 
develop severe cancer therapy-related side-effects or measures to relieve these conditions are 
needed. We focus on identification of human phenotypes in the mucosa to guide further research in 
the field.  
 
Abstract  
Objective: Cancer therapy-induced inflammation of oral and gastrointestinal mucosa affects 
patients non-uniformly. Preventive strategies are limited; no biomarker exists for pretreatment 
identification of patients likely to be severely affected. Animal models are preferred for studying 
molecular responses in mucosa during chemotherapy, but translation into clinical practice is 
difficult. We performed a systematic review to retrieve papers that described molecular changes in 
human mucosa during cancer therapy.  
Study Design: We searched MEDLINE and Ovid Embase searches for English-language literature 
from January 1990 to November 2016 and studies referenced in selected papers, that analyzed 
human mucosa from patients at risk of developing mucositis during cancer therapy. Two authors 
extracted data according to predefined data fields, including study quality indicators.  
Results: We identified 17 human studies on chemotherapy (n=9) and radiotherapy (n=8), but no 
targeted therapy studies. Studies were heterogeneous regarding patient cohort, analysis methods, 
cancer treatment, biopsy timing, and correlations to clinical mucositis. Consequently, meta-analysis 
was not feasible.  
Conclusions: Few human studies described the molecular responses of normal mucosa to cancer 
therapy. Studies were heterogeneous with sparse correlations to clinical mucositis. We proposed a 
model for acquiring data on treatment- and disease-specific phenotypes and transcriptomes for 
predictive or preventive initiatives.  
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Mucositis is an acute, and potentially dose-limiting, adverse effect of cancer therapy. It 
presents as oral and/or gastrointestinal inflammation.
1,2
 Upon chemotherapy (CT) initiation, 
mucositis appears clinically after 7-10 days, and it spontaneously resolves at approximately one 
week after treatment cessation.
3,4
 For patients treated with radiotherapy (RT), a dose-response 
relationship was apparent
5,6
; mucositis generally appeared after a cumulative dose of 30 Grey.
7,8
 




At the molecular level, cancer therapy inflicts direct DNA damage.
12-14
 Cytokines (TNF-α, 
IL-1β, and IL-6) enter the circulation and activate an inflammatory cascade (via NF-κB).
4,15-18
 Both 
intrinsic and extrinsic apoptotic pathways are upregulated and mucosal integrity is compromised by 
inflammatory infiltrates and tight junction disruption.
19,20
 This process leads to further tissue 
damage, involving matrix metalloproteinases (MMPs) and other effectors.
21
 Additionally, cancer 
therapy disrupts the microflora, reducing its diversity and load; this imbalance paves the way for 
opportunistic infections or the reactivation of latent viruses.
21-30
  
Nevertheless, patients are differentially affected by mucositis and the clinical impact has 
been thoroughly described previously.
3,9,31,32
 Compared to mild occurrences (NM), ulcerative  
mucositis (UM) is associated with a high incidence of fever, diarrhea, nausea, and opportunistic 
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infections. Patients with UM often require severe pain relief, may require a feeding tube, and 
generally require prolonged hospitalization.
2,32-35
 Consequently, UM continues to be a considerable 




The current model of mucositis pathogenesis is based primarily on animal studies.
4,18,21,38-41
 
It has been difficult to translate findings from those studies into clinical practice.
42
 Therefore, 
current preventive options for mucositis are few,
37,43-48
 and biomarkers are needed for the 
pretreatment identification of patients likely to develop severe mucositis.
49
  
Consequently, the objective of this study was to provide an overview of the studies that analyzed 
the molecular changes in normal human mucosa during cancer therapy. The entire gastrointestinal 
tract has a common developmental history, and several studies have shown that different sections 
displayed a similar mucositis pathology.
4,39,50,51
 Consequently, we conducted a systematic review to 
identify studies that described molecular changes in normal human mucosa (oral and 
gastrointestinal) from patients at risk of developing mucositis that recieved cancer treatment. 
Finally, based on our findings, we proposed a method to guide future research with a “presicion 
medicine” approach.   
METHODS 
This review was performed according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA).
52
 A protocol was registered at the International Prospective Register of 
Systematic Reviews (PROSPERO ) database, accessible at 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017059447  
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Only clinical studies that involved patients in cancer treatment that were at risk of developing 
mucositis were eligible for this review. For inclusion, the studies had to describe molecular changes 
in normal human oral mucosa and/or gastrointestinal mucosa 
Exclusion criteria 
Papers were excluded for the following reasons: (1) animal studies; (2) tissues other than mucosa 
were analyzed (e.g., blood or saliva); (3) only brush biopsies were studied; (4) only 
histomorphology was described; (5) published only as a conference abstract; (6) published in a 
review; and (7) published in a language other than English. 
Information sources 
We identified studies by searching the electronic databases, MEDLINE and Ovid Embase (January 
1990 – November 2016). Moreover, we scanned the reference lists of the selected papers to identify 
additional articles. An updated search was performed at the end of December, 2016.  
Search 
We determined an appropriate search strategy by combining medical subject headings (MeSH) and 
EMTREE headings with natural language terms. Based on that strategy, we used the following 
search terms: mucositis, stomatitis, gene expression, biomarker, chemotherapy, radiotherapy, 
targeted therapy, cancer, neoplasms. A full detailed description of the search strategy appears in the 
Supplementary Table, S1 (available at [URL/link *]). We removed duplicate references with the 
EndNote tool. 
Study selection 
Two independent reviewers (MM, CS) screened records and selected papers according to inclusion 
criteria. Any disagreement was resolved by consensus. The abstracts of the selected papers were 
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screened based on the exclusion criteria. The flowchart of the literature retrieval process is shown in 
Figure 1.   
A total of 5184 records (after removing duplications) were identified and screened according to the 
inclusion criteria. This process resulted in the removal of 5157 records. Of the remaining 22 
records, the abstracts were screened, and an additional 4 records were removed, because only 
histomorphology or brush biopsies were studied.
53-56
 Next, the full text of 18 papers were assessed, 
and four papers were removed; two papers were only available in the form of a conference 
communication, 
57,58
 one was published in German,
59
 and one compared normal tissue to tumor 
tissue.
60
 Finally, 14 full-text articles were deemed eligible, and these were included in the 
analysis.
17,18,50,61-71
 The reference lists of the retrieved papers were screened for additional papers, 
and three more papers were identified.
72-74
  The final analysis included 17 papers (Table I). Of the 
17 papers, nine analyzed CT treated mucosal tissues, and eight described RT treated mucosal 
tissues.  
Data collection process 
Data was extracted from the papers by two independent reviewers (MM, CS), according to 
predefined criteria. We extracted the following data: first author’s name, year of publication, 
number of study subjects, number of healthy control subjects, type of cancer, type of treatment, type 
of tissue analyzed, time from commencing therapy to tissue biopsy, method used to analyze tissue, 
performance of clinical mucositis assessment (yes/no) and the method used, biological process 
analyzed, and study conclusions. 
Risk of bias assessment 
The selected papers were evaluated for the risk of bias with the Meta Analysis of Statistics 
Assessment and Review Instrument (MAStARI) from the critical appraisal tools for Comparable 
Cohort / Case Control Studies.
75
 The risk of bias was classified as high (up to 49% score “yes”), 
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moderate (50% to 69% score “yes”), or low (more than 70% score “yes”). A risk of bias summary is 
shown in supplementary Table S2 (available at [URL/link *]).  
RESULTS 
Chemotherapy 
A biomarker for mucositis severity was proposed in only one of the nine studies on CT treated 
patients.
65
 That study included a homogenous cohort of 50 patients with colorectal cancer that 
received 5-Fluorouracil (5-FU). They studied thymidylate synthase (TS), a key enzyme that controls 
DNA replication, which is targeted by 5-FU. They reported that low expression of TS was 
associated with grades 2-5 mucositis, based on the WHO mucositis assessment scale.  
 A global gene expression analysis (GGE) was applied in two studies.
62,63
 One study examined 
archived autopsy specimens from nine patients with various cancers that received different types of 
CT (doxorubicin, cyclophosphamide, or 5-FU).
62
 They found no genes that were correlated with 
clinical data, and the time from CT to biopsy was variable miscellaneous. However, that gene 
expression analysis showed a common trend in patients that developed mucositis. They found 
upregulations in genes involved in DNA repair, the response to DNA damage, innate immunity, 
inflammation, and bacterial invasion. Despite robust statistical analyses, that study was weakened 
by its lack of clinical data, lack of a healthy control group, and the heterogeneity in the patient 
cohort. Nevertheless, that study served as proof-of-concept that gene expression data may be 
successfully retrieved from archival material, despite RNA degradation.  
The second GGE study described molecular changes in buccal mucosa from four patients 
treated with cytarabine/daunorubicin for acute myeloid leukemia (AML).
63
 Clinical data on 
mucositis was collected, but it was not correlated to the microarray data. However, they reported 
that, among eight significantly altered genes, the gene that encodes argininosuccinate synthase 1 
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(ASS1) was three-fold downregulated; ASS1 suppresses nitric oxide production, and consequently, 
promotes p53-mediated apoptosis. Moreover, they found that a gene encoding a zinc transporter 
(SLC39A6) was three-fold upregulated. The zinc transporter is involved in the epithelial-
mesenchymal transition and tissue repair. Those results were validated in a polymerase chain 
reaction assay. Although strict statistical analyses (LIMMA and SAM packages with significance 
set at p-values <.01) were performed, only four patients were included; therefore, the results were 
considered preliminary.  
TUNEL is a labeling method for detecting apoptotic cells in tissues. This technique was 
applied in two studies.
50,72
 Both studies included cohorts (n=20 and n=23) of patients with various 
cancers (e.g., breast, gastric, colorectal, lung, non-Hodgkin´s lymphoma, and chronic myeloid 
leukemia), and the patients received various types of chemotherapy. A seven-fold increase in 
apoptotic activity was observed in the intestinal mucosa the first day following chemotherapy. 
Apoptosis gradually declined, and the tissue returned to normal after 16 days.
72
 The same pattern 
was observed in oral mucosa, where apoptosis gradually increased, peaked on day three, then 
declined, and the tissue returned to normal after 11 days. However,  in both studies, the apoptosis 
pattern was not correlated with the grade of mucositis.  
The  pro- and anti-apoptotic family of Bcl proteins was studied using the patient cohort 
studies by Keefe et al. 2000.
64,72
 Among the Bcl proteins, p53 is a transcription factor involved in 
initiating apoptosis, cell cycle arrest, and DNA repair. They found that p53, Bax, and Bak levels 
increased within one day following chemotherapy, and Mcl-1 levels decreased. However, those 
results were not correlated to clinical mucositis.  
The inflammatory mediators, cyclooxygenase2 (COX2), prostaglandin E synthase (mPGES), and 
nuclear factor-kappa-B (NF-κB) were studied in patients with various solid cancers that had 
received various types of CT.
31,17
 A correlation was demonstrated between mucositis severity and 
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elevated levels of COX2 and mPGES observed at10 days after CT administration. However, this 
correlation was not statistically significant, probably because it was based on only three subjects.
17
  
NF-κB and COX2 were also elevated after CT, but these changes were not correlated to mucositis 
severity.
31
   
Tissue permeability and inflammatory mediators in the oral mucosa of 23 patients from the 
Gibson et al 2006 study were analyzed with immunohistochemistry (IHC).
50,61
  They found 
alterations of the following proteins in these tissues: claudin-1, ZO-1, occludin;  IL-1β, IL-6, TNFα, 
MMP-2, and MMP-9. The results were not correlated to clinical mucositis.  
Radiotherapy 
The eight studies retrieved on mucosa affected by RT applied primarily IHC (no GGE analysis). 
They probed tissues for selected inflammatory, apoptotic, and proliferative markers.
66-71,73,74
 Seven 
studies analyzed oral mucosa in patients with head and neck cancer,
66,67,69-71,73,74
 and one study 
analyzed archived radiated colonic mucosa (Table II).
68
 Most of these studies showed some degree 
of correlation between the molecular data and clinical mucositis. However, no specific biomarker 
was proposed in any of these studies.  
One study identified a correlation between mucositis severity and both short- and long-term 
elevated expression of 27E10 in submucosal macrophages.
73
 Other macrophage subtypes (markers 
25F9, CD163), granulocytes (marker CD15), and T-lymphocytes (markers CD3, CD4, CD8) were 
not similarly altered in expression.  
Inflammation was generally the dominant theme throughout these studies. A transmembrane 
glycoprotein highly expressed in macrophage lineages, CD68, was elevated in patients expressing 
the level of grade 1 mucositis.
67
 Many leukocyte subtypes (e.g., CD106-expressing cells) were 
downregulated after RT; in contrast, cells that expressed CD11b/CD18 and CD49d were 
upregulated, and persisted in the tissues for long periods.
70,71
 However, these findings were not 
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correlated to mucositis severity. Another study compared the expression of the inflammatory 
markers, NF-κB and  COX-2, in patients that received either short-term radiotherapy or long-term 
RT combined with 5-FU. They found no differences in expression, which suggested that 
inflammation persisted in radiated tissues.
68
 
Investigations of endothelial permeability markers (CD54,CD106, and E-selectin) showed that the 
pattern of expression of these markers changed with both short-term and long-term treatments. 
Moreover, the transmembrane membrane adhesion signaling protein, beta2-integrin, was elevated, 
but beta1-integrin remained unchanged with radiotherapy.
74
   
Three studies demonstrated epithelial proliferation and raised levels of cytokeratin in response to 
RT.
66,67,69
 Following an initial period of apoptosis, epithelial proliferation started during the first 
week after radiotherapy.
67,69
 IHC results showed the presence of Ki-67, the proliferation marker, 
and increased expression of [
3
H]-TdR, a marker of DNA synthesis. These findings were 
demonstrated by comparing expression in tissues with grade 1 mucositis to expression in tissues 
without mucositis from the same patients.  
DISCUSSION 
The mucosa is composed of a multi-layer of epithelial cells with a high turnover rate 
supported by connective tissue. Originally, cancer therapy-induced mucositis was considered to be 
solely the result of genotoxic injury (apoptosis). It was thought to primarily affect cells in the basal 




Murine models have been preferred in studies of the molecular biology of mucositis. Breaking the 
mucosal barrier in a neutropenic or mucositis affected patient by taking a biopsy may potentially 
allow bacteria or fungi to enter the blood stream. This risk of sepsis may have restrained researchers 
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or ethic committees to approve these kind of studies.
17
 The animal studies have demonstrated that 
mucositis pathology is driven by apoptosis and inflammation. 
 The mechanisms are initiated immediately upon cancer therapy induction, both in the 
submucosa and in the epithelium, before any clinically visible damage occurs.
4,18,19,38,78,79
 However, 
the integrity of the mucosa arises through a variety of mechanisms, including antigen-presenting 
dendritic cells (DCs). As part of the innate immune surveillance system, DCs monitor changes in 
oral microflora. This surveillance involves sampling the antigenic environment, and then presenting 
a “peptide menu” to T-cells, via their cell surface major histocompatibility complex class II 
receptors (MHC Class II).
80
 Thus, DCs are highly important in the induction of tolerance or 
inflammation.
81
 Although DCs are also present in intestinal mucosa, the concentration of DCs is 
considerably higher in buccal mucosa than in mucosa in other regions.
81-84
  
A comparison of human and mouse model responses to inflammation has shown poor 
correlations; they displayed different alterations in gene expression, particularly those involved in 
B-cell receptor signaling, macrophage and monocyte function, and the expression over time of the 
alpha chain of the class II histocompatibility antigen, human leukocyte antigen-D-related (HLA-
DR).
85
 Thus, it remains debated whether mouse models are relevant to studies of human disease. 
Due to the complexity of the factors involved in mucositis pathology (host response, microbiome, 
treatment modality, severity), the mechanisms underlying this condition might be best addressed in 
studies of human tissues.
42,86
 Additionally, in animal models, oral mucositis often must be 
provoked, for example, by scratching the mucosa, which may distort the results.
79,87,88
 Finally, when 
drugs were given to reduce the damage caused by RT by blocking some of the molecular pathways 
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The studies retrieved in this systematic review reassert that apoptosis is not the only factor 
involved in mucositis pathogenesis. Endothelial permeability is increased, inflammatory cells are 
attracted, and an array of inflammatory mediators is detectable in the tissues. Moreover, tight 
junction permeability is increased, which leads to mucosal microbiome involvement. Early defense 
mechanisms are instituted through anti-apoptotic mediators, restoration of epithelial proliferation, 
and cytokeratin production. Finally, short term microvasculature damage (aggregation of blood 
components and coagulation) may prolong the effect of CT locally because of reduced ability to 
remove damaging agents or long term damage in RT affected mucosa (telangiectasia, sclerosis and 
fibrosis) may impair healing . 
68, 93,94
However, of the retrieved papers, only two studies found a 
correlation between the molecular events in the tissues and the severity of clinical mucositis.
65,73
 
Therefore, no meta-analysis was possible, due to the heterogeneity in study designs.  
Several studies implied that a strong genetic component was associated with mucositis. 
Some genomic polymorphisms had predictive value, including modifications in genes that encoded 
drug-metabolizing enzymes, e.g. DRYD, the UGT1A1*28 allele or polymorphisms in genes that 
encoded p53 and MDM2.
93,94,95,96
 A SNP-based Bayesian network was constructed, based on 
saliva-extracted DNA from 216 patients with various hematologic malignancies that were treated 
with human stem cell transplantation (HSCT). This SNP network could predict severe mucositis 
with a predictive validity of 81.2%.
53
 That study assumed that only the type of drug, not the type of 
cancer, influenced the incidence of mucositis. In a second study, which included 972 patients 
suffering multiple myeloma and treated with HSCT, eleven SNPs located near the MMP13 gene 
were associated with mucositis grade 2-4.
54
 But, to our knowledge, the findings from the above-
mentioned studies have not been implemented clinically to adjust or individualize chemotherapy, 
with the aim of reducing the incidence of mucositis.
97
 This fact is partly due to the low positive 
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predictive value of the tests.
98-100
. However, these data offer the potential for selecting patients for 
enrollment in clinical trials that aim to develop prevention strategies.
101
  
Currently, there is a lack of studies that integrate phenotypic data with genomic data in the 
progress towards finding robust predictive biomarkers for mucositis. The importance of using 
human tissues to reveal phenotypes that may guide genotyping studies was well illustrated in a 
study by Santini et al.
65
 Those authors found that low expression of thymidylate synthase, a key 
enzyme in the  control of DNA replication and a target for 5-FU in tissues, was associated with 
grades 2-5 mucositis. A later study revealed that this result was due to polymorphisms in the gene 
that encoded thymidylate synthase.
102
 Another recent study conducted under similar conditions 
(identical disease, treatment, and time interval for biopsy) proposed that differential gene splicing 
may account for heterogeneity in mucositis phenotypes.
103
 They described a splice variant of HLA-
DRB1 in epithelial dendritic cells that distinguished patients with UM from patients with NM. 
We suggest conducting a number of pilot studies that are similar in nature to the studies 
described in this literature review. But, the pilot studies should have comparable designs and should 
be conducted under similar conditions. The design should include serial human mucosa biopsies 
with concurrent draws of peripheral blood, and patients with high-risk mucositis should receive 
different treatment regimens. Moreover, “omics” methodologies should be applied to the tissue 
samples to investigate correlations between molecular and clinical data.  
This proposed model has some limitations. One limitation is the number of times that we 
can sequentially biopsy any one patient. However, this limitation may be even more restrictive in 
animal studies, because animals are typically sacrificed at biopsy.
38,104
  Another limitation is the risk 
involved with taking mucosal biopsies during active cancer treatment. Breaking the mucosal barrier 
for a biopsy puts the neutropenic patient at risk of developing a complicating infection. This 
concern may complicate the ethics of these studies, which may impede institutional approval.
17
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However, among the human studies included in this review,  no complications related to taking a 
biopsy were reported. Moreover, no biopsy-related complications were reported in a recent study on 
10 patients with multiple myeloma that underwent 30 biopsies during HSCT treatment.
103
 Strict 
sterility during the biopsy procedure and tight suturing may prevent infectious invasion; 
furthermore, the wound healing mechanisms were apparently intact during the cancer therapy.  
The proposed model includes detailed, chronologic, molecular analyses of the human 
mucosa before, during, and after treatment, with clinical parameter measurements. The aim of this 
approach is to reveal the molecular pathways associated with mucositis phenotypes. International 
collaborations will be important for adding volume and structure to these studies. However, they 
must be conducted with standardized data sampling techniques, and overall, they must be aligned 
with the concept of precision medicine, as proposed by the National Research Council.
105,106 
The 
ultimate goal would be to generate a drug- or disease-specific UM classification system, which 
could provide relevant, precise taxonomy of the pathologic processes. This information would 
support clinical decisions in determining the most appropriate care for each patient. 
CONCLUSIONS 
Few human studies have described the molecular responses of normal mucosa to cancer 
therapy. Those studies are heterogeneous in nature, with sparse correlations that point to markers 
for clinical mucositis. Nevertheless, some studies have revealed that disease- and treatment-specific 
transcriptomes exist. Therefore, we have proposed a model for future studies, which will facilitate 
the discovery of transcriptomes correlated to treatment- and disease-specific phenotypes. That 
information will provide a basis for predictive and preventive initiatives.  
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Figure 1. Flow diagram showing the procedure for selecting studies for this systematic review.   
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Table I. Publications retrieved from our systematic literature search, chemotherapy  
Paper No  Cancer 
type 














231 Various Chemotherapy 
miscellaneous   
oral 
mucosa 
7 Day 0 up to 
+11 
IHC Yes# claudin-1, ZO-1 







Increased tissue permeability through tight 
junction damage. Increase in inflammatory 
cytokines IL-1β, IL-6, TNF, MMP-2 and MMP-
9. No correlation to clinical mucositis.  
Mougeot 
201333 





archive    
No Miscellaneous,    
less than 30 
days 
GGE No Various Proof-of-concept study showing extraction of 
eligible microarray data from FFPE-treated 
specimens. Alterations seen in pathways of 
apoptosis, DNA repair, innate immunity, 

















Pre-treatment AML-specific immune 
deregulation. Post-treatment inflammatory 
damage and p53 induced inhibition of apoptosis  
Lalla 
201035 




No Day -10; +10; 
+28; +100  
PCR Yes* COX-2; mPGES Inflammatory markers COX-2 and mPGES 
peaked at day +10. A correlation between pain 
scores and mucositis severity.  Pilot study. 
     
Logan 
200736 




4 Day 0 up to 
+11 
IHC Yes# COX-2; NF-kB  The inflammatory mediators COX-2 and NF-kB  









4 Day 0 up to 
+11 
TUNEL Yes# terminal 
deoxynucleotidyl 
transferase (TdT) 
Apoptosis occur before day 3 upon 
chemotherapy administration, starts to decline 
after 6 days, but has not returned to pre-




232 Various Chemotherapy 
miscellaneous   
duodenal 
mucosa 
 Day 0; +1; +3; 
+5; +16.  
IHC No p53  
Caspase-3 
Bax  
Apoptotic markers of the Bcl-2 family, Bax/Bak 
and p53 increased upon initiation of 
chemotherapy and returned to normal level at 
Comment [A1]: AUTHOR: Two different versions 
of Table 1 and 2 captions were provided and the 
one in the manuscript has been used. Please check 
and confirm that it is correct. 
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50 Colorectal 5-Fluorouracil colonic 
mucosa 
No Day 0 IHC Yes WHO Thymidylate 
synthase 
Low expression of thymidylate synthase, a key 
enzyme controlling DNA replication and a target 
for 5-FU was associated with grade 2-5 




232 Various Chemotherapy 
miscellaneous   
duodenal 
mucosa 
 Day 0; +1; +3; 
+5; +16 
TUNEL No terminal 
deoxynucleotidyl 
transferase (TdT) 
TdT a marker of apoptotic activity was seven-
fold increased at day one. 
 
 
   
Abbreviations:  No=number of patients enrolled in the study. 1: Wardil 2016 and Gibson 2006 uses the same patient cohort. 2: Bowen 2005 and Keefe uses the same patient cohort. AML=acute myeloid 
leukemia. MM=multiple myeloma. HSCT=high dose chemotherapy with autologous stem cell support. 5-FU= 5-fluorouracil. HCG=Healthy Control Group. GGE=global gene expression; 
IHC=immunohistochemistry; PCR=Polymerase Chain Reaction. OMI=. COX=cyclooxygenase; mPGES,=microsomal prostaglandin E synthase. IL=interleukin. TNF=tumor necrosis factor. NK-kB=nuclear 
factor kappa-light-chain-enhancer of activated B cells. Bax, Bak, Mcl-1= members of the intrinsic apoptotic pathway Bcl-2 family regulated by p53 activated caspase-3. TUNEL= terminal deoxynucleotidyl 
transferase dUTP nick end labelling (a method for detecting DNA fragmentation). TdT= Terminal deoxynucleotidyl transferase.  FFPE=formalin fixed and paraffin embedded. #Unspecific or no annotation of 
applied method; * Oral Mucositis Index (OMI) according to Schubert et al 1992. WHO=mucositis assessment according to World Health Organization (Quinn et al 2007) 
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Table II. Publications retrieved from our systematic literature search, radiotherapy 





















7 Before and  
after 2 weeks 
 
IHC Yes WHO CD68   
p53      
Ki-67  
Grade 1 mucositis is associated with increased number 
of inflammatory CD68 positive cells (macrophages), 
apoptosis (p53) and the presence of the cell proliferation 
marker Ki-67.  
 






No Before and  
after 3 weeks 
 
IHC Yes WHO Cytokeratin 1 
Cytokeratin 6  
Cytokeratin 10  
Cytokeratin16 
 
Grade 1 mucositis is associated with increased levels of 
cytokeratin 1, 6, 10, 14 and 16 compared to non-
mucositis areas reflecting a defense towards radiation.  
 
Yeoh 2005 28 Colorectal  
Mixed 
Radiotherapy  






No Miscellaneous          
4-65 days     
IHC Yes# NF-kB; COX-2 Comparing short term RT with long term RT/5-FU the 
inflammatory markers NF-kB and  COX-2 were equally 
expressed. Microvascular injury (telangiectasia, fibrosis 
and sclerosis) was associated with raised levels of  NF-
kB and  COX-2 




No Miscellaneous          




Yes* [3H]-TdR Restoration of epithelial proliferation after initial 
apoptosis is initiated following the first week of 
radiation as measured by the expression of [3H]-TdR, a 












 Before, at 
60Gy and 6-12 
months after 
RT 
IHC No ICAM-1 (CD54) 










Subepithelial endothelium (markers CD54,CD106 and 
E-selectin) and subtypes of leucocytes (markers 
CD11b/CD18, CD11a /CD18, CD49d, 27E10, 25F9, 
CD163) were investigated. The expression of CD106 
was downregulated after RT, whereas CD11b/CD18 and 
CD49d positive cells increased. After RT the radiated 
tissues have a reduced number of vessels and a different 
pattern of endothelial adhesion proteins as well as 












No Before, at 
60Gy, and 6 
month after 







Sub-epithelial endothelium (markers CD54,CD106 and 
E-selectin) and subtypes of leucocyte (markers 
CD11a/CD18, CD11b/CD18, CD49d, 27E10, 25F9, 
CD163) were investigated.  RT causes sub-epithelial 
migration of leucocytes which reverses to normal after 
cessation of RT. However some migrated cells persist in 
the tissues 6 month after RT (CD11b/CD18 and CD49d 
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positive cells)  A different pattern of adhesion 
molecules and macrophages subpopulations is are seen 
after RT.  











No Before, at 
30Gy and 
60Gy 







Subtypes of macrophages (markers: 27E10, 25F9, 
CD163),               granulocytes (marker CD15) and T-
lymphocytes (markers CD3, CD4, CD8) were 
investigated. Only 27E10 positive macrophages 
increased upon RT indicating an intermediate 
inflammatory response. There was a positive correlation 















No Before, at 
30Gy and 
60Gy 








The transmembrane membrane signaling protein beta2-
integrin increased while beta1-ingegrin stayed 
unchanged upon RT. The endothelial adhesion proteins 
CD54 and CD62E increased in expression while CD106 
remained at low levels.  
 
Abbreviations:  No= number of patients enrolled in the study. Ni=not indicated; HNC=head and neck cancer. SCC= squamous cell carcinoma. Gy=Grey; 5-FU=5-fluorouracil; HCG=Healthy Control Group; 
RT=radiotherapy; IHC=immunohistochemistry; [3H]-TdR= tritiated thymidine; WHO=mucositis assessment according to World Health Organization (Quinn et al 2007); #Unspecific or no annotation of  
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Toxicity of the oral and gastrointestinal mucosa induced by high-dose melphalan is a clinical
challenge with no documented prophylactic interventions or predictive tests. The aim of this
study was to describe molecular changes in human oral mucosa and to identify biomarkers
correlated with the grade of clinical mucositis.
Methods and Findings
Ten patients with multiple myeloma (MM) were included. For each patient, we acquired
three buccal biopsies, one before, one at 2 days, and one at 20 days after high-dose mel-
phalan administration. We also acquired buccal biopsies from 10 healthy individuals that
served as controls. We analyzed the biopsies for global gene expression and performed an
immunohistochemical analysis to determine HLA-DRB5 expression. We evaluated associa-
tions between clinical mucositis and gene expression profiles. Compared to gene expres-
sion levels before and 20 days after therapy, at two days after melphalan treatment, we
found gene regulation in the p53 and TNF pathways (MDM2, INPPD5, TIGAR), which
favored anti-apoptotic defense, and upregulation of immunoregulatory genes (TREM2,
LAMP3) in mucosal dendritic cells. This upregulation was independent of clinical mucositis.
HLA-DRB1 and HLA-DRB5 (surface receptors on dendritic cells) were expressed at low
levels in all patients with MM, in the subgroup of patients with ulcerative mucositis (UM), and
in controls; in contrast, the subgroup with low-grade mucositis (NM) displayed 5–6 fold
increases in HLA-DRB1 and HLA-DRB5 expression in the first two biopsies, independent of
melphalan treatment. Moreover, different splice variants of HLA-DRB1 were expressed in
the UM and NM subgroups.
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Conclusions
Our results revealed that, among patients with MM, immunoregulatory genes and genes
involved in defense against apoptosis were affected immediately after melphalan adminis-
tration, independent of the presence of clinical mucositis. Furthermore, our results sug-
gested that the expression levels of HLA-DRB1 and HLA-DRB5 may serve as potential
predictive biomarkers for mucositis severity.
Introduction
For three decades, high-dose melphalan, supported with autologous stem cell transplantation
(HSCT), has been a component of treatment for patients with newly diagnosed multiple mye-
loma (MM) [1]. However, melphalan induce adverse effects, including inflammation of the
oral and gastrointestinal mucosa (mucositis) and prolonged neutropenia, which necessitates
HSCT [2]. Melphalan induced mucositis occurs inconsistently, because although 80% of
patients experience some degree of mucositis, only 40% are affected severely [2, 3]. Severe tox-
icity unfolds as a loss of mucosal integrity, severe diarrhea, and painful oral ulcers; i.e., ulcera-
tive mucositis (UM) [3]. Complicated by bacterial or viral infections, these patients more often
experience nausea, diarrhea, febrile episodes, and longer hospital stays compared to patients
with mild or no mucositis (NM) [4, 5]. At present, international recommendations consist of
infection control and palliative measures for pain relief [6]. Despite intense research efforts, no
methods exist for preventing or reducing the duration of mucositis, and no predictive tests are
available [7].
The mechanisms of action and metabolism of melphalan are well-described [8]. Melphalan
alkylates DNA, which causes cross-links to form between DNA strands, and subsequently,
DNA is degraded through apoptosis. The drug is administered intravenously, metabolized in
the liver, and excreted through feces and urine. The degree of toxicity depends on renal func-
tion, body mass index (BMI), gender, and performance status [2, 9]. However, none of these
factors are predictors of UM.
The current model of mucositis pathology is generalized across treatment regimens [10].
Initially, cancer therapy-induced DNA damage activates the intrinsic pro-apoptotic Bax/Bak
and p53 pathways, and reactive oxygen species (ROS) are released [11, 12]. Simultaneously,
damage to the extracellular matrix induces the release of inflammatory cytokines, which acti-
vate the extrinsic apoptotic pathway via tumor necrosis factor alpha (TNF-α) [13, 14]. This
release is followed by an inflammatory response, which includes upregulation of the interleu-
kins (IL) IL-1β, IL-6, IL-10, transforming growth factor-beta (TGF-β), nuclear factor-kappaB
(NF-κB), and matrix metalloproteinases (MMPs) [15, 16]. This model is mainly based on
murine studies and a few human studies, but to the best of our knowledge, no study has
focused on patients with MM that were treated with melphalan.
Recent genome-wide association studies (GWAS) of patients that underwent HSCT have
implied that UM development is associated with a genetic predisposition, primarily related to
immune function [17, 18]. One study included 153 patients with miscellaneous malignancies
that underwent HSCT, with the aim of building a predictive network for UM, based on 82
selected single nucleotide polymorphisms (SNPs) [17]. The network was subsequently tested
in a cohort of 16 patients, and in the absence of any false positives, the predictive validity of the
network was 81.2%. A later study included 972 patients with MM that underwent HSCT, and
they identified 11 SNPs located near the matrix metalloproteinase gene that were associated
Gene Expression Analysis of Melphalan Affected Oral Mucosa
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with UM and several known clinical risk factors. The sensitivity of predicting UM was 52%
[18]. Apart from the low sensitivity, those studies were limited by their failure to identify phe-
notypes or causal relationships.
Here, we present a global gene expression study on oral mucosa biopsies and peripheral
blood cell samples from consecutive patients with MM that were treated with high-dose mel-




This study included 30 patients, aged 18 years or older, recruited from the Aalborg University
Hospital, from September 1st 2010 to September 1st 2012. Patients with MM (n = 20) were
recruited from the Department of Hematology. Healthy individuals (CON, n = 10) were
recruited for a control group from the Department of Maxillofacial Surgery. Of the 20 MM
patients, seven withdrew consent before any intervention; one was missed due to earlier start
of treatment, which was not communicated to the research unit; and two withdrew after the
first biopsy without giving any reason. The remaining 10 patients provided three sequential
buccal biopsies and peripheral blood samples. The first biopsy was obtained immediately
before they received high-dose melphalan (day0); the second was obtained after the autologous
stem cell reinfusion (day2); and the third was obtained during an outpatient control visit
(day21). The CON group comprised 10 healthy, non-smoking, age- and gender-matched indi-
viduals. Controls provided one buccal biopsy and peripheral blood sample. One CON individ-
ual was later diagnosed with the autoimmune disease, psoriasis (CON09), and hence, this
subject was not included in the statistical analysis. The North Denmark Region Committee on
Health Research Ethics approved the clinical protocol (N-20100022). Informed written con-
sent was obtained from all patients, in accordance with the Declaration of Helsinki.
All patients with MM underwent a comprehensive, initial evaluation, including a medical
history and clinical examination. Age, gender, and Eastern Cooperative Oncology Group
(ECOG) performance status were recorded at baseline, in addition to the subtype of MM and
the time from diagnosis to entering HSCT. The criteria for determining the level of organ
involvement at diagnosis was based on the degrees of elevated calcium, renal failure, anemia,
and bone lesions (CRAB criteria) [19]. Furthermore, patients were screened for dental infec-
tions and, when indicated, these infections were eradicated prior to chemotherapy.
All patients with MM received a standard induction regimen, which consisted of cyclophos-
phamide 500 mg/m2 delivered intravenously (i.v.) on days 1 and 8; bortezomib 1.3 mg/m2
delivered subcutaneously (s.c.) on days 1, 4, 8, and 11; and dexamethasone 20 mg, delivered
orally (p.o.) on days 1–2, 4–5, 8–9, and 11–12, repeated every third week, 3 times. After this
treatment, patients were primed with cyclophosphamide 2 g/m2 and recombinant granulocyte
stimulating factor (rhG-CSF), before their circulating CD34+ hematopoietic stem cells were
harvested with leukapheresis [1]. Only patients without progressive disease were assigned to
HSCT. These patients received a high dose of melphalan (200 mg/m2), followed by infusion of
autologous hematopoietic stem cells. All patients with MM had received standard antiviral,
antifungal, and antibacterial treatment, according to department protocols.
Mucositis and diarrhea assessments
Signs of oral mucositis (OM) were recorded daily for patients with MM during the hospital
stay (from administration of chemotherapy to discharge). OM signs were identified according
to the WHO oral toxicity assessment worksheet [20], and they included subjective symptoms
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(pain and ability to eat solid food) and objective findings (erythema, ulceration) in predefined
regions of the mouth (lip, check, tongue, floor of the mouth, and soft palate). Grades 0 and 1
(NM) included increasing soreness, with or without erythema, but solid food could be taken.
In grades 2 to 4 (UM), food intake gradually declined, due to pain and ulcerations, and paren-
teral feeding might have become necessary. The maximum OM grade recorded during treat-
ment was considered the patient’s general mucositis experience. Diarrhea was estimated
according to the Common Terminology Criteria for Adverse Events (CTCAE), issued by The
National Cancer Institute of the National Institutes of Health [21]. In grades 1 to 2, vomiting
increases from one to two episodes in 24 h to three to five episodes in 24 h. Grade 3 included
more than 6 episodes in 24 h, and grades 4 to 5 were considered life-threatening, and could
gradually lead to death. Diarrhea data were gathered retrospectively, from medical records.
Biopsy
All biopsies were acquired in a standardized manner. First, the mouth was thoroughly rinsed
with chlorhexidine and local anesthesia was applied (0.5 ml Citanest1: prilocain 30 mg/ml
+ felypressin 0.54 μg/ml; Dentsply, York, PA, US). Then, a 5-mm lens-formed biopsy of the
buccal mucosa, approximately 1 cm inferior to the papilla parotidea, was taken with a scalpel.
The wound was tightly sutured with resorbable vicryl 4.0 (Ethicon, Sommerville, NJ, US).
Patients were instructed to rinse twice daily with chlorhexidine until suture removal, after 10
days. One-half of the biopsy was immediately immersed in RNAlater™ (Ambion, Thermo-
fischer Scientific, Waltham, MA, US) for 24 h; then, it was frozen at -80˚C until analysis. The
other half of the biopsy was fixed in 10% neutral-buffered formalin, and within 1½ days, it was
embedded in paraffin and maintained at room temperature until further preparation.
Peripheral blood
Within 2 h of taking the biopsy, 15 ml EDTA-mixed venous full blood was drawn. Mononu-
clear cells (MNCs) were isolated with an in-house standard purification protocol. This proto-
col follows the manufacturer’s guidelines for Ficoll-PaqueTM (GE Healthcare, Little Chalfont,
Buckinghamshire, UK); density gradient centrifugation in LeukosepR tubes (Greiner Bio-One
GmbH, Frickenhausen, Germany). Purified MNCs were suspended in freezing medium con-
taining 10% dimethyl sulfoxide, in units of 5 million, vital frozen at -196˚C in liquid nitrogen,
and stored frozen until analysis.
Gene expression
The frozen oral mucosa samples were homogenized with TRIzolR Reagent (Invitrogen, Ther-
moFischer Scientific), and total RNA was isolated with the mirVanaTM miRNA Isolation Kit
(Ambion/Invitrogen, ThermoFischer Scientific) according to the manufacturer’s protocol.
RNA amplification was performed with the AmbionR WT Expression Kit (Applied Biosystems,
ThermoFischer Scientific), according to the manufacturer’s instructions, starting with 100 ng
total RNA, on a TP Basic Thermocycler, real time PCR instrument (Biometra, Göttingen, Ger-
many). The quality of the RNA product was evaluated on the NanoDrop spectrophotometer
and the 2100 Bioanalyzer with the Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa
Clara, CA, US). We prepared the RNA samples for hybridization to Affymetrix GeneChip
Human Exon 1.0 ST Arrays with the Affymetrix GeneChip WT Terminal Labeling and Controls
Kit (P/N 901524) (Affymetrix, Santa Clara, CA, US), according to the manufacturer’s instruc-
tions. CEL files were generated with Affymetrix GeneChip Command Console Software and
deposited at the NCBI Gene Expression Omnibus repository, under number GSE81979. A simi-
lar procedure was applied to analyze gene expression in MNCs isolated from blood samples.
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Immunohistochemistry
We cut 4-μm-thick biopsy tissue sections and mounted them on glass coverslips. Following an
in-house optimized protocol, tissues were stained with an antibody against the HLA class II
Histocompatibility antigen, DR beta 5 chain (HLA-DRB5 center region) with a rabbit poly-
clonal antibody (no. OAAB06426, Aviva Systems Biology, CA, US). Normal tonsil tissue was
used as a positive control. The stained slides were then scanned on a Hamamatsu NanoZoomer
slide scanner and analyzed with NDP viewer software. To estimate the number of cells that
stained positive for HLA-DRB5, each stained slide was searched for a hot spot; then, this spot
was framed with a 0.75×0.4 mm (0.3 mm2) rectangle; the area included approximately half lam-
ina epithelialis and half lamina propria. We counted all cells in the frame that were distinctly
stained with anti-HLA-DRB5 antibodies. The analyzer was blinded to the mucositis grade.
Statistical analysis
Power estimation of group size. To identify genes that varied more than two-fold
between test points with a false discovery rate of less than 0.05% and a power of 90%, we
applied the method described by Lee and Whitmore [22], implemented in the R-package, size-
power (Qui 2008). We found that 10 patients in each group were sufficient for detecting signif-
icant differences.
Statistical analysis. All statistical analyses were performed with R [23] version 3.2.0 and
Bioconductor packages [24]. The p-values adjusted for false discovery rates were controlled
with the Benjamini-Hochberg method [25], for each of the above tests. Adjusted p-values
below 0.05 were considered significant.
The CEL files produced by the Affymetrix Expression Console and the probes were prepro-
cessed and summarized to gene level with the RMA algorithm in the Bioconductor package
‘affy’, based on custom CDF files [26]. This preprocessing resulted in the gene expression levels
of 38,830 genes for each Exon array each annotated with Ensembl gene (ENSG) identifiers.
Patient CON09 was included in the normalizations of the gene expression data, but excluded
in the statistical analysis.
With patient ID as a cluster variable, we used the linear model for microarray data (limma
package in R), a mixed linear model, and an empirical Bayes approach to test for significant
differences in gene expression levels between day2 and day0, and between day21 and day0
[27]. For the peripheral blood samples, we only compared day0 and day21 to baseline, because
only two blood samples were analyzable for day2. We performed an unpaired test with the
limma package to test for significant differences in gene expression between patients on day0
and controls.
The patients were divided into UM or NM groups, according to their mucositis experience.
We used the limma package to detect significant genes that were differentially expressed
between the two groups at each time point.
We applied the Mann-Whitney test to test for the relationship between mucositis severity
and duration of neutropenia, leukopenia, and thrombocytopenia. We also used the Mann-
Whitney test to evaluate differences between groups in the numbers of in-hospital days and
years of progression free survival (PFS).
Results
The clinical characteristics and demographics of the included patients prior to HSCT are
shown in Table 1. No signs of infection at the site of biopsy were reported. The clinical data
collected during the HSCT and at follow up are shown in Table 2. UM (grades 2–4) was
observed in 4 patients, and NM (grades 0–1) was observed in 6 patients. The average mucositis
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scores were 1.5 (range 0–4) for the whole cohort, 3.3 for the UM group, and 0.3 for the NM
group. The average diarrhea scores were 2.2 (range 1–4) for the whole cohort, 3.3 (range 3–4)
for the UM group, and 1.5 (range 1–2) for the NM group. The average hospital stays were 22.6
Table 1. Patient characteristics and demographics upon enrollment in the study.
Patient Age Gender ECOG Weight MM CRAB Induction cycles Response induction Standard HSCT Diagnosis to HSCT
MM01 62 f 2 69 IgG-κ B 3 No PD Y 5.3
MM02 51 m 0 110 IgG-λ B 3 No PD Y 3.9
MM04 66 f 0 70 IgG-κ R 3 No PD Y 3.7
MM05 67 m 1 92 IgG-κ B 3 No PD Y 4.6
MM07 67 m 0 63 IgG-κ C 3 No PD Y 143
MM09 63 f 1 60 IgG-κ B 3 No PD Y 3.9
MM15 69 f 0 72 IgG-κ A 3 No PD Y 36.8
MM18 64 f 2 52 IgG-κ R 3 No PD Y 5.1
MM19 64 m 0 90 IgG-κ B 3 No PD Y 4.1
MM20 62 f 1 97 IgG-λ B 3 No PD Y 3.8
Abbreviations: ECOG = Eastern Cooperative Oncology Group performance status at baseline. MM = multiple myeloma subtype. CRAB = end-organ damage
at diagnosis (C = hypercalcemia, R = renal failure, A = anemia, B = bone lesions) [19]. Induction cycles = Cyclophosphamide 500 mg/m2 i.v. days 1 and 8;
Bortezomib 1,3 mg/m2 s.c. days 1,4,8, and 11; Dexamethasone 20 mg p.o. days 1–2, 4–5, 8–9, and 11–12, repeated every third week. PD = progressive
disease, HSCT = high dose chemotherapy (melphalan 200 mg/m2) with autologous stem cell transplantation. Diagnosis to HSCT = months between the
diagnosis of MM and the HSCT procedure.
doi:10.1371/journal.pone.0169286.t001

















Patients with ulcerative mucositis
MM04 2 3 4 4 10 41 4.5 CR
MM18 4 4 6 6 12 29 3.1 VGPR
MM19 4 3 10 8 10 21 3.0 VGPR
MM20 3 3 10 10 6 24 3.0 CR
Patients with no/mild mucositis
MM01 0 2 10 10 14 24 4.1 Relapse
MM02 0 1 12 8 14 17 4.5 CR
MM05 1 2 6 6 14 21 3.2 Relapse
MM07 0 2 8 4 20 16 1.5 Relapse
MM09 0 1 10 8 10 17 1.0 Relapse
MM15 1 1 8 6 10 16 2.2 Relapse
Abbreviations: HSCT = high-dose chemotherapy (melphalan 200 mg/m2) and autologous stem cell transplantation; PFS = progression free survival; the
surrogate marker for overall survival was defined as the time from entering HSCT to disease progression, death, or follow-up [19]; CR = complete response;
VGPR = very good partial response; Relapse = clinical relapse.
1 Calculated according to WHO mucositis assessment scale [20]. Patients that experienced mucosal ulcerations during treatment were considered to have
ulcerative mucositis, WHO grades 2–4; patients with only soreness or erythema were considered to have none/mild mucositis, WHO grades 0–1.
2 Calculated according to the Common Terminology Criteria for Adverse Events [21]
3 Neutropenia was defined as <0.5×106/l
4 Leukopenia was defined as <0.5×109/l
5 Thrombocytopenia was defined as <150×109/l.
6According to the International Uniform Response Criteria for multiple myeloma [19].
doi:10.1371/journal.pone.0169286.t002
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days (range 16–41) for the whole cohort, 28.8 days (range 21–41) for the UM group, and 18.5
days (range 16–24) for the NM group. The difference in hospital stays was statistically signifi-
cant (p = 0.020). The duration of neutropenia was not significantly different between UM and
NM groups, but thrombocytopenia was significantly prolonged in the UM compared to the
NM group (p = 0.047). PFS [28] was not statistically different between the UM and NM
groups. The CON and MM groups were comparable in age (CON: age 58 y, range 47–78 vs.
MM: age 63.5 y, range 51–69) and gender (CON: females 4/10 vs. MM: females: 6/10).
Analysis of gene expression in mucosa samples
All 40 biopsies (3×10 patients and 1×10 controls) provided gene expression profiles. No statis-
tically significant differences in gene expression were found between the MM group on day0
and the CON group. Patients with MM showed no significant changes in gene expression
between day0 and day21. However, 35 genes in patients with MM showed significantly differ-
ent expression between day0 and day2 (Table 3). The gene expression levels were independent
of clinical mucositis. The dominant gene alterations were observed in apoptosis-related genes,
followed by genes related to inflammatory/immunologic response, transcription factors, and
members of the Histone Cluster family. We also observed alterations in genes related to
metabolism.
Gene expression related to mucositis grade
When we compared unsupervised gene expression profiles between NM and UM, we found
that no genes were significantly differentially expressed in the blood. In contrast, in the biopsies,
two genes of the major histocompatibility complex (MHC) Class II: HLA-DRB1 and HLA-DRB5
were significantly differentially expressed at the first two time points (Table 4). Patients with
UM and CON expressed the same low level of HLA-DRB1 and HLA-DRB5, but patients with
NM expressed significantly higher levels (Fig 1). The expression levels of HLA-DRB1 and HLA-
DRB5 were independent of melphalan administration. Of the 10 CON subjects, one patient,
CON09, showed high levels of HLA-DRB1 and HLA-DRB5 expression, similar to the levels
observed in the NM group. We reopened the protocol and returned to the patient to reaffirm
his health status. We found that subject CON09 had a mild case of psoriasis that was not re-
ported at the baseline interview. An alternative splicing analysis revealed that patients with NM
and the CON09 subject expressed a different isoform of HLA-DRB1 (NM_001243965) than that
expressed by patients with UM (NM_002124.1). However, the difference in HLA-DRB5 expres-
sion between groups was not due to different isoforms.
Immunohistochemistry
In hematoxylin and eosin-stained specimens, no gross anatomical changes were observed in
the epithelial or mesenchymal layers. In general, both the epithelium and stroma were repre-
sented in equal amounts. However, two specimens that were cut at a tangential angle that
revealed only superficial layers were excluded from the histological analysis (MM15_1 and
MM18_2). Generally, when present, cells that stained positive for HLA-DRB5 were localized in
the lower part of the epithelial layer, near the basal membrane, around the papillae, and in the
upper part of the lamina propria. Faint, diffuse HLA-DRB5 staining of the endothelium was
not included in the assessment. Examples of high HLA-DRB5 expression/low-grade mucositis
(MM01) and low HLA-DRB5 expression/severe-grade mucositis (MM18) are shown in Fig 2.
A dotplot of the numbers of cells that stained positively for HLA-DRB5 is shown in Fig 3, and
these findings supported the gene expression analysis.
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Gene expression in peripheral blood
Of the blood samples drawn from 10 patients with MM, we successfully performed gene
expression profiles in 8 out of 10 drawn on day0 and day21, but only 2 out of 10 drawn on
Table 3. Genes altered in the buccal mucosa of patients with multiple myeloma.
Gene
symbol
FC p-value adjusted p-
value
Qualified GO term Function
Upregulated genes day2 versus baseline
MDM2 2.69 2.37e-15 3.07e-11 MDM2 oncogene, E3 ubiquitin protein ligase Apoptosis
EDA2R 2.63 1.85e-15 3.07e-11 Ectodysplasin A2 receptor Apoptosis
CUL9 2.25 1.26e-15 3.07e-11 Cullin-9 Apoptosis
INPPD5 2.18 8.39e-14 4.66e-10 Inositol Polyphosphate-5-Phosphatase Apoptosis
TIGAR 2.17 7.08e-10 8.87e-07 Chromosome 1 open reading frame 5 Apoptosis
E2F7 2.06 2.60e-13 1.05e-09 E2F transcription factor 7 Apoptosis
NCR3LG1 2.70 1.14e-10 1.94e-07 Natural killer cell cytotoxicity receptor 3 ligand 1 Immune
response
LAMP3 2.26 4.39e-06 0.0011 lysosomal-associated membrane protein 3 Immune
response
TREM2 2.12 2.78e-09 2.92e-11 Triggering receptor expressed on myeloid cells Immune
response
FKBP5 2.04 6.66e-05 0.0082 FK506 Binding Protein 5 Immune
response
POLH 2.42 1.60e-14 1.24e-10 Polymerase; DNA directed Transcription
ARNTL 2.40 2.65e-06 0.00080 Aryl hydrocarbon receptor, nuclear translocator-like Transcription
NFIL3 2.20 4.29e-05 0.0011 Nuclear factor, interleukin 3 regulated Transcription
ABCA12 4.73 8.87e-07 0.00034 ATP-binding cassette sub-family A, member 12 Metabolism
CEL 4.64 3.68e-15 3,58e-11 Carboxyl ester lipase Metabolism
CA2 2.57 9.99e-10 1.18e-06 Carbonic anhydrase II Metabolism
SLC39A6 2.53 1.16e-10 2.00e-07 Solute carrier family 39 Metabolism
SPATA18 2.19 2.16e-12 6.98e-09 Spermatogenesis associated 18 Metabolism
P3H2 2.10 2.28e-09 2.46e-06 Prolyl 3-Hydroxylase 2 Metabolism
F3 2.09 0.00037 0.027 Coagulation Factor III Metabolism
GLS2 2.01 4.79e-14 3.1e10 Glutaminase 2 Metabolism
WDR63 2.84 7.16e-11 1.35e-07 WD Repeat Domain 63 Unknown
RN7SL519P 2.05 0.00061 0.037 Pseudogene Unknown
Downregulated genes day2 versus baseline
SERPINB10 -2.12 1.75e-06 0.00574 Serpin peptidase inhibitor, clade B member 10 Apoptosis
NR1D2 -2.57 9.63e-06 0.00201 Nuclear Receptor Subfamily 1, Group D, Member 2 Transcription
NR1D1 -2.29 0.00015 0.0142 Nuclear Receptor Subfamily 1, Group D, Member 1 Transcription
CIART -2.38 9.14e-05 0.0103 Circadian associated repressor of transcription Transcription
HIST1H1A -2.56 8.31e-07 4.18e-06 Histone Cluster 1, H1a Transcription
HIST1H1B -2.04 6.70e-09 6.60e-06 Histone Cluster 1, H1b Transcription
HIST1H3J -2.00 8.31e-07 0.00033 Histone Cluster 1, H3j Transcription
OXGR1 -2.04 8.93e-05 0.010 Oxoglutarate (Alpha-Ketoglutarate) Receptor Cell signaling
PER3 -2.76 1.77e-05 0.0032 Period Circadian Clock Metabolism
CYSLTR1 -2.91 8.72e-06 0.0019 Cysteinyl Leukotriene Receptor 1 Cell structure
KIF20A -2.05 4.65e-08 3.22e-05 Kinesin Family Member 20A Cell structure
PIK3C2G -2.06 4.8e-06 0.00121 Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing gamma
polypeptide
Cell growth
Abbreviations: FC = fold change; GO = gene ontology annotation
doi:10.1371/journal.pone.0169286.t003
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day2 (MM20 and MM05). Consequently, we performed an unsupervised global gene analysis
of peripheral MNCs by comparing the MM day0 samples to CON samples (disease vs. healthy)
and MM day0 samples versus MM day21 samples (before vs. after treatment). We found that
two genes that encoded B-cell surface markers (CD22, CD200) were downregulated in MM
day0 samples compared to CON samples, and these genes were further downregulated on
day21, though the differences from day0 were not significant. The levels of CD22 and CD200
expression were independent of the mucositis grade.
Discussion
This study described the gene signature of buccal mucosa samples from patients with MM dur-
ing HSCT. We found that this signature was dominated by altered expression of inflammatory
and anti-apoptotic genes, but expression was independent of the presence of clinical mucositis.
Table 4. Genes altered in the buccal mucosa of patients with multiple myeloma that displayed mild/no mucositis (NM) compared to those that dis-
played ulcerative mucositis (UM).
Gene symbol FC p-value adjusted p-value Qualified GO term Function
NM versus UM day0, before melphalan
HLA-DRB1 6.27 2.96e-07 0.00573 Human Leukocyte / Major Histocompatibility Antigen Class II DRB1 beta chain Immune response
HLA-DRB5 5.64 2.7e-07 0.00573 Human Leukocyte / Major Histocompatibility Antigen Class II DRB5 beta chain Immune response
NM versus UM day2 after melphalan
HLA-DRB1 5.81 2.01e08 0.00039 Human Leukocyte / Major Histocompatibility Antigen Class II DRB1 beta chain Immune response
HLA-DRB5 5.56 1.98e09 7.69e05 Human Leukocyte / Major Histocompatibility Antigen Class II DRB5 beta chain Immune response
FC = fold change; GO = gene ontology annotation.
doi:10.1371/journal.pone.0169286.t004
Fig 1. Genes differentially expressed according to mucositis grade. Expression of (a) HLA-DRB1 and (b) HLA-
DRB5 genes in buccal mucosa biopsies taken at baseline (day0), two days (day2), and 21 days (day21) after high-dose
melphalan therapy. Patients with mild/no mucositis (NM) express 6–8 fold more HLA-DRB1 and 4–5 fold more HLA-DRB5
than patients with ulcerative mucositis (UM). Melphalan treatment did not affect expression of HLA-DRB1 or HLA-DRB5 in
either group. One healthy control (CON09) expressed the same high levels of HLA-DRB1 and HLA-DRB5 as those
observed in the NM group. Subject CON09 was diagnosed with the autoimmune disease, psoriasis. Previous studies have
reported that patients with psoriasis were 77% less likely to develop mucositis than patients without psoriasis [54].
doi:10.1371/journal.pone.0169286.g001
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Furthermore, we identified a specific isoform of the immunomodulatory gene, HLA-DRB1,
which may serve as a biomarker for mucositis severity.
The process that leads to mucositis is triggered immediately upon initiation of cancer ther-
apy and before any visible macroscopic damage [10]. Moreover, eventual UM coincides with
neutropenia, within 7–10 days of starting chemotherapy. Therefore, to avoid compromising
Fig 2. Immunohistochemical analysis of HLA-DRB5 expression in oral mucosa biopsies. Oral buccal
mucosa (×20 magnification) staining shows HLA-DRB5 expression in the center region (a) High HLA-DRB5
expression is observed in the patient MM01 with mild mucositis. (b) Low HLA-DRB5 expression is observed in the
patient MM18 with severe mucositis. Generally, when present, cells that stained positive for HLA-DRB5 are
primarily localized in the lower part of the epithelium, near the basal membrane, around the papillae, and in the
upper part of the submucosa in close proximity to the basal membrane. A weak, diffuse HLA-DRB5 staining of the
endothelium is also visible. Normal tonsil tissue was included on the slide as a control; these appear identical in (a)
and (b). The square insets highlight the morphology of one of the HLA-DRB5 expressing cells that displayed
extensions, similar to those observed in dendritic cells.
doi:10.1371/journal.pone.0169286.g002
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patients with neutropenia, we acquired the second biopsy before the onset of neutropenia.
With this approach, the biopsy was unlikely to comprise disintegrated tissue that, presumably,
would be dominated by inflammatory mediators. Instead, we aimed to gain insight on the cel-
lular processes that gave rise to the inflammatory state. Mucositis lasts for approximately 7
days, and then, it spontaneously resolves. We acquired the third biopsy on day 21, when the
mucosa was fully restored.
Little is known about the effects of melphalan on normal epithelium, but in cancer cells, mel-
phalan induces oxidative stress and upregulates a wide range of apoptosis-related genes [8, 29],
consistent with our findings of EDA2R upregulation. EDA2R encodes a TNF receptor that
mediates the activation of NF-κB and jun-N-terminal (JNK) pathways, which lead to caspase-
initiated apoptosis. Previous studies reported that these pathways were activated in buccal
mucosa of patients with various cancers that received HSCT [30–32], and in gastrointestinal
mucosa of patients treated with 5-fluoruracil [33]. In contrast, we found upregulated expression
Fig 3. The number of cells that stained positive for HLA-DRB5 in oral mucosa biopsies. A dotplot shows the
cell count performed on oral mucosa biopsies that had been immunostained to detect HLA-DRB5. Each biopsy was
examined to determine hot spots of expression; then, this section was framed with a rectangle of 0.75×0.4 mm (0.3
mm2), and all distinctly stained cells within the rectangle were counted.
doi:10.1371/journal.pone.0169286.g003
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of INPP5D, which encodes a membrane protein in hematopoietic cells. The INPP5D protein
negatively regulates JNK signaling and limits Fas-FasL-induced apoptosis in T-cells found at
mucosal surfaces [34]. In addition, we identified five genes involved in suppressing the pivotal
p53 apoptotic pathway. Four of these were upregulated: MDM2, CUL9, E2F7, and TIGAR; and
one was downregulated: SERPINB10. The MDM2 gene encodes a protein ligase that ubiquiti-
nates p53, and thus, inhibits p53-mediated cell cycle arrest and apoptosis. A previous gene
expression study on three patients with acute myeloid leukemia used the same time intervals
between biopsies that we used, and they found MDM2 upregulation [35]. In an array of studies,
p53 has been identified as a key regulator of apoptosis, which leads to mucositis [11, 12, 36].
However, the gene alterations associated with apoptosis observed in our study, including
EDA2R, did not depend on the level of clinical mucositis.
We found several genes related to transcription that were altered to favor DNA repair. For
example, POLH was upregulated; POLH encodes a specialized DNA polymerase that accu-
rately replicates UV-damaged DNA. Conversely, members of the histone cluster family (e.g.,
HIST1H1A), NR1D1, and NR1D2 were downregulated. These results implied that defense
against apoptosis and DNA damage was a central objective in the initial stage of mucositis.
Importantly, this objective was independent of the mucositis grade, which implies that other
factors must be involved in distinguishing UM and NM.
The immune response was activated at an early stage, through the upregulation of TREM2
and LAMP3 on day2. Both these genes encode DC membrane proteins that contribute to T-
cell activation and mucosal inflammation. The LAMP3 gene is specifically expressed in mature
DCs [37, 38]. TREM2, which is expressed on both DCs and macrophages, can bind and phago-
cytose yeasts, Gram positive bacteria, and Gram negative bacteria [39], which are commonly
present in the oral cavity [40]. Generally, DCs are potent antigen-presenting cells that respond
to microbial exposure by secreting abundant cytokines; e.g., IL-12 and type I interferon. In
turn, IL-12 mobilizes natural killer (NK) cells. The NCR3LG1 gene, which encodes a ligand
that triggers NK cells, was also upregulated [41]. Several studies have shown that an important
aspect of mucositis pathology is the thinning of the epithelium, in combination with changes
in the composition and concentration of the oral and gastrointestinal microbiota [13, 42, 43].
Our results confirmed the notion that the host immune response towards the microbiome
played a dominant role, early in mucositis pathogenesis; however, these responses were not
associated with mucositis severity.
Among several genes associated with metabolism, ABCA12 and CEL were upregulated
4.7-fold and 4.6-fold, respectively, on day2. ABCA12 encodes a membrane transporter protein
primarily involved in the keratinocyte lipid-barrier that maintains homeostasis in the epider-
mis [44]. To the best of our knowledge, no previous study has described a role for ABCA12 in
the mucosa, but it most likely performs a similar function of barrier protection. CEL encodes a
lipase with multiple functions in lipid metabolism; it is also expressed in macrophages [45].
The expression levels of both these genes were unaffected by clinical mucositis.
Gene alterations associated with clinical mucositis grade
When we compared the gene expression profiles between the six patients with NM and the four
patients with UM, we found two genes that were more highly expressed in NM patients:
HLA-DRB1 and HLA-DRB5 (Fig 1). The HLA-DRB1 and HLA-DRB5 genes are related members
of the MHC Class II family, located on chromosome 6p21.32. They encode surface proteins that
are almost exclusively expressed on specialized antigen presenting cells, including macrophages,
B-cells, and DCs or Langerhans cells [46, 47]. These surface receptors function as a ligand for
the T-cell receptor, and their primary function is to capture potentially foreign antigens on the
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cell surface and to present them for recognition by CD4+ T-cells [48]. Thus, they form a com-
munication between the innate and adaptive immune systems, and determine whether to bring
forth resistance or tolerance, in addition to taking up and processing dying cells [49].
Several pharmacogenomic GWAS studies were recently performed on drug toxicity, which
showed that HLA Class I and II paralogs were associated with toxicity [50] or inflammatory
mucosal conditions [51, 52]. Even more interestingly, certain HLA-DRB1 alleles (HLA-DRB115)
have been detected in patients with MM that were exposed to bisphosphonates and developed
osteonecrosis of the jaw [53].
We conducted a search for alternatively spliced variants of HLA-DRB1 and HLA-DRB5 and
found two isoforms of HLA-DRB1 (NM_001243965 and NM_002124). According to the
UCSC genome browser, NM_001243965 harbors six exons, and NM_002124 harbors an
extended isoform within seven exons. We found that patients with NM expressed the longer
transcript variant of HLA-DRB1 (NM_002124), and patients with UM and healthy subjects
(CON) expressed the shorter variant (NM_001243965). No splice variant was found for
HLA-DRB5; however, that gene was expressed at different levels. We found that HLA-DRB5
was expressed 4.5 to 5 times more frequently in the NM group than in the UM group, in the
first two of three biopsies. These findings were confirmed in an immunohistochemical analysis
of HLA-DRB5 in the biopsies (Fig 3). Furthermore, cells that stained positively for HLA-DRB5
were localized primarily in the epithelium and submucosa, relatively close to the basal mem-
brane, and these cells displayed a morphology similar to DCs (Langerhans cells).
In contrast to the other healthy subjects, CON09 (a patient with psoriasis) expressed the
long transcript variant of HLA-DRB1 and a high level of HLA-DRB5 protein, similar to
patients in the NM group. Previous reports have indicated that patients with psoriasis are 77%
less likely to develop mucositis [10, 54]. Psoriasis is an auto-inflammatory skin disorder with
reduced apoptosis. It is known that patients with psoriasis express certain HLA-DRB1 alleles
[55]. Our results suggested that mechanisms related to inflammatory and/or apoptotic path-
ways may be common in psoriasis and low-grade mucositis in MM. In addition, ABCA12
expression was upregulated in CON09 compared to the other healthy subjects. Previous gene
expression studies on patients with psoriasis confirmed this finding [56].
The two recent GWAS studies on patients that received HSCT identified SNPs near the locus
of MMP and other genes related to inflammation, but none related to HLA-DR [17, 18]. Other
recent studies found a major role for MMPs in mucositis pathology [57]. We did not find any
changes of that nature in our material. The phenotypes described in our study may provide addi-
tional information to guide future GWAS studies [50]. Recent studies have shown that induction
therapy with immune modulating agents reduced the frequency and severity of mucositis [58];
our results may provide additional knowledge to elucidate the development of those therapies.
In peripheral blood, we did not find any differences in gene expression between NM and UM
groups, at any time point. However, among all patients with MM, CD22 and CD200 were downre-
gulated on day0 compared to controls. Both these genes encode cell membrane glycoproteins of
the immunoglobulin superfamily. CD200 is expressed in multiple cell types, including B-cells, T-
cell subsets, DCs and endothelial cells. In contrast, CD22 is exclusively expressed on mature B-cell
lineages [59, 60]. Low CD200 expression has been linked to prolonged survival among patients
with MM [61]. In our cohort, the lowest CD200 expression levels were observed among patients
with UM; however, the levels were not significantly different between UM and NM groups.
Study strengths and limitations
There was some concern that breaking the mucosal barrier by taking a biopsy during chemo-
therapy might lead to potential fatal infections. We could reject this concern, because none of
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our patients experienced any infection related to the biopsy; only mild discomfort was re-
ported. This finding was also reported in previous studies [15, 35, 36, 62]. Therefore, we con-
cluded that our method would be safe for patients undergoing HSCT, provided that the
second biopsy is taken before the onset of neutropenia. The major limitation of the study was
the low number of subjects. We designed the study to identify genes that were altered by more
than 2-fold between time points, with a false discovery rate of less than 0.05% and a power of
90%. However, because our method of harvesting human mucosa during high-dose melphalan
treatment was controversial, we sought to include the least possible number of patients re-
quired to draw valid conclusions. However, we recognize that the power of this study was set
to estimate any fold-changes above two, and false negative findings may be concealed. Conse-
quently, we did not expect to elucidate the full, true picture; nevertheless, we brought to light
some important biological associations, which have motivated us to continue this research and
confirm the results in a larger cohort.
Conclusions
Currently, there is a great need to develop a clinically applicable method for identifying poten-
tial susceptibility to toxicity among patients before treatment initiation. We found that patients
with NM displayed upregulations of HLA-DR1 and HLA-DRB5 compared to patients with UM
and healthy individuals. These genes encode proteins expressed on the surface of antigen pre-
senting cells in mucosa, which suggested that the immune response might play a major role as
a primary effector in UM. Indeed, the results suggested that expression of a certain isoform of
HLA-DRB1 might diminish the inflammatory response to melphalan toxicity. However,
because the levels of HLA-DRB1 and HLA-DRB5 expression were constant throughout treat-
ment, this isoform may serve as a predictor of UM. The findings in this study were based on a
small number of samples, and thus, our results must be validated in a larger patient cohort.
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Objectives: Radiation-therapy (RT) induces mucositis, a clinically challenging condition with 
limited prophylactic interventions and no predictive tests. In this pilot study, we applied global 
gene-expression analysis on serial human oral mucosa tissue and blood cells from patients with 
tonsil squamous cell cancer (TSCC) to identify genes involved in mucositis pathogenesis. 
Materials and Methods: Eight patients with TSCC each provided consecutive buccal biopsies and 
blood cells before, after 7 days of RT treatment, and 20 days following RT. We monitored clinical 
mucositis and performed gene-expression analysis in tissue samples. We obtained control tissue 
from nine healthy individuals. 
Results: After RT, expression was upregulated in apoptosis inducer and inhibitor genes, EDA2R 
and MDM2, and in POLH, a DNA-repair polymerase. Expression was downregulated in six 
members of the histone cluster family, e.g., HIST1H3B. Gene expression related to proliferation and 
differentiation was altered, including MKI67 (downregulated), which encodes the Ki-67-
proliferation marker, and KRT16 (upregulated), which encodes keratin16. These alterations were 
not associated with the clinical mucositis grade. However, the expression of LY6G6C, which 
encodes a surface immunoregulatory protein, was upregulated before treatment in three cases of 
clinical none/mild mucositis, but not in four cases of ulcerative mucositis.  
Conclusion: RT caused molecular changes related to apoptosis, DNA-damage, DNA-repair, and 
proliferation without a correlation to the severity of clinical mucositis. LY6G6C may be a potential 
protective biomarker for ulcerative mucositis. Based on these results, our study model of 
consecutive human biopsies will be useful in designing a prospective clinical validation trial to 
characterize molecular mucositis and identify predictive biomarkers. 
3 
Introduction 
Treatment-related toxicity remains a major concern in patients with head and neck cancers [1-3], 
including squamous cell cancer of the tonsil (TSCC). The incidence of TSCC is increasing, due to a 
shift towards younger patients with human papilloma virus (HPV)-positive cancers [2,9]. 
Consequently, more survivors must live with both short- and long-term cancer treatment side 
effects, including mucositis, hypo-salivation, tissue fibrosis, and hypo-vascular bone [10,11].  
For curative intentions, radiation therapy (RT) is a key modality, with or without surgery, combined 
with concomitant chemotherapy. Squamous cell carcinomas require a relatively large amount of 
radiation (60 to 70 Gray [Gy]) [4]. Recently, outcomes have improved with the advent of radio-
sensitizers and intensity-modulated RT. However, mucositis remains an acute, painful side effect 
[5]. Mucositis appears clinically at a total dose of approximately 35 Gy (after about 2 weeks), and it 
gradually worsens with each dose delivered [3,6]. The incidence of mucositis is 85% in patients 
with head and neck cancers that require RT; of these, 37% require hospitalization, and of these 51% 
require a feeding tube [7,8]. The lack of predictability of who are severely affected is a significant 
clinical challenge [12]. Palliative interventions may relieve the side effects, but no preventive 
medications are available that can reduce mucositis, and no markers are available for pretreatment 
identification of patients likely to be severely affected [13]. Previous studies have shown that RT 
causes DNA damage and oxidative stress, which subsequently lead to activation of p53-induced 
radiotoxic pathways, apoptosis, and cell-cycle arrest [14-16]. Furthermore, DNA repair and damage 
response via MDM2 suppression of p53, was also reported a consequence of RT in addition to 
radiation fibrosis, and endothelial damage [17-18]. However, no studies have described a gene 
expression analysis of human mucosa [19]. 
Here, we describe a disease- and treatment-specific global gene expression (GGE) pilot study. We 
examined consecutive mucosa biopsies and peripheral blood cells collected from patients with 
4 
TSCC during RT treatment. This study aimed to generate phenotypic data to document the 
feasibility of a novel in vivo model of consecutive human biopsies during RT treatment that might 
provide new biological knowledge of the molecular pathogenesis of severe mucositis and facilitate 
the identification of potential predictive biomarkers.  
Materials and methods 
Patients 
The Committee on Health Research Ethics of the Northern Denmark Region (N-20100022) 
approved the clinical protocol for this study. Informed written consent was obtained from all 
patients, in accordance with the Declaration of Helsinki. Patients were enrolled from September 1, 
2010, to April 30, 2013. Inclusion criteria were age 18 years, cancer-treatment naïve, and without 
uncontrolled competitive disease. 
We recruited 19 patients at the Department of Maxillofacial Surgery, Aalborg University Hospital. 
Among those patients, nine displayed histologically confirmed TSCC and a metastasis-negative 
FDG-PET/CT scan. Of these nine patients, seven provided three consecutive buccal biopsies and 
peripheral blood samples. The first biopsy and blood sample set (baseline) was acquired before the 
start of RT, the second set was acquired after one week of RT, and the third set was acquired at an 
average of 20 days after the last RT, for outline of the study plan (Fig 1). Two of the nine included 
patients died during treatment; one after the second biopsy and one before the first biopsy. The 
patient that died after the second biopsy was included in the analysis; thus, we analyzed eight 
patient samples. Our control group comprised 10 healthy, non-smoking individuals that had 
participated in a previous study [20]. Of these, one was excluded, due to an autoimmune disease 
that was not reported at the time of biopsy; thus, nine control samples were analyzed. All patients 
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underwent pretreatment evaluations, including a medical history, smoking habits (smokers were 
defined as smoking  more than 10 cigarettes per day), alcohol consumption (consumers were 
defined as drinking more than 21 units of alcohol weekly), and a clinical examination. Baseline 
characteristics were noted, including age, gender, and Eastern Cooperative Oncology Group 
(ECOG) performance status. Before RT, patients were screened for dental infections, and when 
indicated, infections were eradicated. 
TSCC tumors were staged according to the TNM system for staging cancer (T = size of primary 
tumor; N = presence and level of lymph node involvement; M = presence of distant metastasis) 
[21]. Immunohistochemistry was performed to detect p16 overexpression in the tumor, which 
indicated HPV-induced TSCC. All patients with TSCC received intention-to-cure treatments. 
Accelerated external RT was applied in 6 weekly fractions of 2 Gy. RT was supplemented, when 
indicated, with concomitant cisplatin (40 mg/m2) once weekly during RT, according to international 
guidelines [22,23]. We noted the total radiation dose (Gy) applied to the tumor, based on the 
radiation schemes. We also calculated the estimated dose applied to the buccal mucosa at the site of 
the biopsy.  
Mucositis assessment 
Oral mucositis (OM) was evaluated weekly in all patients, by the same researcher (MM), according 
to the World Health Organization oral toxicity assessment worksheet [24]. Subjective symptoms 
(pain and ability to eat solid food) and objective oral mucositis-related findings (erythema, 
ulceration) were noted. Grades 0 and 1 comprised none/mild mucositis (NM); this included 
soreness, with or without erythema, but solid food could be taken. Grades 2 to 4 comprised 
ulcerative mucositis (UM); in UM, food intake gradually declined, due to pain, and parenteral 
feeding might become necessary.  
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Collection of mucosa tissue and blood cells 
Sample collection was performed with the methods described previously [20]. Briefly, a lens-
formed, 5-mm biopsy was harvested in a standardized manner, and the wound was tightly sutured. 
One half of the biopsy was immediately embedded in RNAlater™, for GGE analysis. The other 
half was fixed in formalin and embedded in paraffin for immunohistochemistry.  
Within 2 h of the biopsy procedure, 15 ml of EDTA-mixed venous full blood was collected. Then, 
mononuclear cells were isolated and stored at -196 °C in liquid nitrogen, until analysis.  
Gene expression analysis 
Gene expression was evaluated with the methods described previously in detail [20]. Briefly, for 
both mononuclear cells and mucosa, we used the Affymetrix GeneChip Human Exon 1.0 ST Arrays 
with the Affymetrix GeneChip WT Terminal Labeling and Controls Kit (P/N 901524). CEL files 
were generated with Affymetrix GeneChip Command Console Software and deposited in the NCBI 
Gene Expression Omnibus repository, under number GSE103412. 
Immunohistochemistry 
Tissue blocks were cut in 4-μm sections, and the sections were mounted on glass slides. With an in-
house optimized protocol, tissues were stained for scinderin with a rabbit polyclonal antibody 
(KIAA1905, Nordic Biosite, www.nordicbiosite.com). Stained slides were scanned on a 
Hamamatsu NanoZoomer slide scanner and analyzed with NDP viewer software. To estimate the 
scinderin stain intensity, each stained slide was viewed at a magnification of 15, and evaluated 
within a framed rectangle of 0.75 × 0.4 mm (0.3 mm2). Samples were classified as no stain (0), 
lightly stained (+), or heavily stained (++).  
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Statistical analysis  
All statistical analyses were performed with R  [25] version 3.2.2 and Bioconductor packages [26]. 
Estimation of sample size 
We applied the method described by Lee and Whitmore to identify genes that varied more than 
two-fold between test points, with a false discovery rate (FDR) less than 0.05% and a power of 90% 
[27]. This analysis was implemented in the R-package, size-power (Qui 2008). The results indicated 
that 10 patients in each group would provide sufficient statistical power.  
Data preprocessing 
The CEL files produced by the Affymetrix Expression Console were preprocessed and summarized 
at the gene level with the RMA algorithm in the Bioconductor package, affy, based on custom 
CDF-files [28]. This preprocessing step revealed the expression levels of 38,830 genes for each 
exon array. Genes were annotated with Ensembl gene identifiers. 
Detection of differential expression 
With the patient ID as a cluster variable, we used the limma package, a linear mixed model analysis 
provided in R, and the empirical Bayes approach to test for significant differences in gene 
expression between the second biopsy/blood sample and baseline, and between the third 
biopsy/blood sample and baseline [29]. To test for significantly differentially expressed genes 
between baseline and control samples, an unpaired t-test was performed with limma [29]. Patients 
were divided into two groups based on mucositis status (UM or NM), and significantly 
differentially expressed genes were detected with limma at each time point. 
The FDR-adjusted P-values (0.05) were controlled with the Benjamini–Hochberg method [30] for 
each of the above tests.  
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Hierarchical clustering  
The GGE data set of all nine control samples and the eight TSCC samples were divided into eight 
subsets. These subsets were gene biotypes (defined as protein coding), pseudogenes, miRNA, 
rRNA, snoRNA, snRNA, linRNA, and antisense transcript. Each dataset was subjected to 
hierarchical clustering, where the Pearson correlation was used as a distance measure, and average 
linkage was used as the algorithm method [31]. 
 
RESULTS 
Clinical characteristics of TSCC 
The pilot study design is shown in Fig 1. Three steps of intervention were planned during TSCC-
specific standard therapy, which included RT and cisplatin treatments. We collected 32 biopsies and 
performed 32 blood draws (7 × 3 sample sets + 1 × 2 sample sets for TSCC and 9 × 1 sample set for 
controls).  
 
Fig 1. The pilot study design. Tissue samples were collected from patients with tonsil squamous 
cell cancer (TSCC) at three time points: at baseline, before RT (Day0), after 7 days of RT (Day/), 
and 20 days after the last RT. In addition, tissue samples were collected from healthy subjects 
(CON). All tissue collections consisted of one blood sample and one biopsy of oral buccal mucosa. 
Tissue samples were successively stored in our biobank. Once all the material was collected, gene 
expression analysis was performed collectively at the same laboratory.  
 
9 
Patient clinical characteristics and demographics are shown in Table 1. Age was comparable 
between the control (age 58 years, range 47–78) and TSCC (age 63.5 years, range 51–69) groups. A 
trend towards male dominance was observed in the TSCC group (2 females among 8 patients), but 
not in the control group (4 females among 9 patients). Five of eight patients with TSCC were 
smokers, and four of the eight consumed alcohol. Tumor staging was evaluated according to the 
TMN system [21], and p16 overexpression was detected in six of eight tumors.  
 
Table 1. Patient characteristics and demographics upon enrollment in the study 
Patient Age Gender ECOGa Smokingb Alcoholc Stagingd p16e 
TSCC01 57 m 0 0 0 T1N2bM0 yes 
TSCC03 67 f 2 1 1 T1N0M0 no 
TSCC04 74 m 2 0 1 T1NxM0 no 
TSCC05 72 m 0 0 0 T1N2aM0 yes 
TSCC06 65 m 0 1 1 T1N1M0 yes 
TSCC07 59 m 1 1 1 T2N1M0 yes 
TSCC08 68 m 0 1 0 T4aN2cM0 yes 
TSCC09 56 f 0 1 0 T2N2cM0 yes 
aEastern Cooperative Oncology Group (ECOG) performance status at baseline; bSmoking 
categories: 0 = Non-smoker, 1 = smoked more than 10 cigarettes per day; cAlcohol categories: 0 = 
No alcohol consumption, 1 = consumed more than 3 units of alcohol per day; dTNM system for 
staging of cancer: T = size of primary tumor; N = presence and level of lymph node involvement; 
M = presence of distant metastasis (1); eOverexpression of p16 indicates positive for HPV 
Table 2. Patient clinical data during radiation treatment and at follow-up 
Patient 



















TSCC01 66 Gy/33 fr 4.2 yes 3 3 53 
TSCC03 66 Gy/33 fr 9.5 yes 0 8 42 
TSCC04 68 Gy/34 fr 9.3 yes 1 8 dead 
TSCC05 68 Gy/33 fr 14.4 yes 2 12 41 
TSCC06 66 Gy/33 fr 5.3 no 1 4 40 
TSCC07 68 Gy/34 fr 5.1 yes 3 4 52 
TSCC08 76 Gy/56 fr 6.9 no 2 9 80 
TSCC09 68 Gy/34 fr 7.2 yes 3 6 92 
Abbreviations: Gy: Gray; fr: fractionated; WHO: World Health Organization; amucositis stage, 
according to the WHO assessment scale, was measured weekly, during treatment and after, until 
mucositis dissolved [24].  
 
The clinical data collected during RT are shown in Table 2. After treatment initiation, the second 
biopsy was acquired at a median of 7 days (range 3–12), and the third biopsy was acquired at an 
average of 57 days (range 40–92). Two patients, TSCC06 and TSCC08, did not receive cisplatin. 
An average dose of 68.3 Gy (range 66–76) was applied to the tumors. According to the radiation 
schemes, a total dose of approximately 30–35 Gy was applied to the buccal mucosa bilaterally. At 
the time of the second biopsy, an average dose of 7.7 Gy (range 4.2–14.4) was applied. UM was 
detected in five patients and NM was detected in three patients. The median mucositis scores were 
1.9 (range 0–3): 2.6 for the UM group and 0.7 for the NM group. We observed no signs of infection 
at the site of biopsy. All samples yielded valid gene expression profiles.  
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Gene expression in mucosa and blood 
The differentially expressed genes in mucosa (Table 3) and blood (Table 4) are annotated with a 
gene symbol, the fold change (FC), the adjusted p-value, the gene ontology terms (GO-terms), and 
the gene function. 
Table 3 Genes altered in mucosal tissue from patients with tonsil squamous cell carcinoma 
receiving radiation therapy  
Gene symbol FC p-value adj. p-value Qualified Gene Onotology term Function 
Baseline  
LIFR 
-2.73 2.09e-05 0.019 





















-2.11 1.74e-06 0.010 




















After seven days of radiotherapy  
HIST1H3B -2.91 7.52e-08 0.000143 Histone Cluster 1, H3b Transcription 
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HIST1H2BM -2.75 1.6e-07 0.000251 Histone Cluster 1, H2bm Transcription 
CYSLTR1 -2.54 3.91e-05 0.0098 Cysteinyl Leukotriene Receptor 1 Cell structure 
HIST1H3C -2.39 9.08e-06 0.0039 Histone Cluster 1, H3c Transcription 
HIST1H3H -2.17 4.53e-08 0.000105 Histone Cluster 1, H3h Transcription 
MOXD1 -2.16 6.19e-08 0.000128 Monooxygenase DBH Like 1 Metabolism 
HIST1H1A -2.12 0.00016 0.022 Histone Cluster 1, H1a Transcription 
HIST1H1B -2.09 1.05e-08 3.14e-05 Histone Cluster 1, H1b Transcription 
MKI67 -2.00 2.58e-06 0.0016 Marker Of Proliferation Ki-67 Transcription 
WDR63 2.67 1.09e-10 1.1e-06 WD Repeat Domain 63 Unknown 
MDM2 
2.29 6.77e-11 4.26e-11 
MDM2 oncogene, E3 ubiquitin protein 
ligase 
Apoptosis 
EDA2R 2.26 8.38e-11 1.0e-06 Ectodysplasin A2 receptor Apoptosis 
POLH 2.17 3.22e-10 1.81e-06 Polymerase; DNA directed Transcription 
KRT16 2.15 0.00058 0.052 Keratin 16 Cell structure 
Three weeks after RT cessation 
ANKRD20A5
P -3.56 2.90e-07 0.0026 
Ankyrin Repeat Domain 20           
Family Member A5 
Pseudogene 
CYSLTR1 -3.11 3.92e-06 0.0082 Cysteinyl Leukotriene Receptor 1 Cell structure 
SCIN -2.50 9.09e-05 0.044 Scinderin Cell structure 
ANKRD20A1
1P -2.47 4.93e-05 0.033 




P -2.32 1.2e-06 0.0052 




-2.28 4.1e-05 0.032 
Cytochrome P450 Family 4 Subfamily F 
Member 34 
Pseudogene 
TC2N -2.13 6.47e-05 0.036 Tandem C2 Domains, Nuclear Metabolism 
IL1R2 
-2.12 3.37e-07 0.0026 
Interleukin 1 Receptor Type 2; cytokine 























Table 4 Genes altered in mononuclear cells of the blood from patients with tonsil squamous 










-11.8 1.48e-12 5.80e-08 RNA, U6 small nuclear 620, pseudogene pseudogene 
RNU6-
422P 
-3.77 3.03e-08 0.00022 RNA, U6 small nuclear 422, pseudogene pseudogene 
RNU6-
737P 
-3.36 1.34e-07 0.00034 RNA, U6 small nuclear 737, pseudogene pseudogene 
RNU6-
795P 
-2.85 2.82e-06 0.0024 RNA, U6 small nuclear 795, pseudogene pseudogene 
RPS7P2 -2.63 2.14e-07 0.00044 Ribosomal protein S7 pseudogene 2 pseudogene 
AGAP9 
-2.61 6.15e-06 0.0039 
ArfGAP With GTPase Domain, Ankyrin 




-2.45 5.72e-08 0.00025 RNA, U6 small nuclear 336, pseudogene pseudogene 
OAZ1 
-2.26 6.81e-06 0.0040 Ornithine decarboxylase antienzyme 1 




-2.19 0.00012 0.018 Ribosomal protein L23a pseudogene 64 pseudogene 
RNU6-
1162P 
-2.06 2.02e-05 0.0068 RNA, U6 small nuclear 1162, pseudogene pseudogene 
CCDC144B -2.02 0.00074 0.043 Coiled-Coil Domain Containing 144B pseudogene 
RN7SL432
P 
-2.02 5.37e-07 0.00088 RNA, 7SL, cytoplasmic 432, pseudogene pseudogene 
RNU6-
622P 
7.30 7.74e-09 8.62e-05 RNA, U6 Small Nuclear 622, Pseudogene pseudogene 
DUTP6 
3.45 1.74e-06 0.0019 





3.44 1.07e-07 0.0014 
RNA Polymerase II CTD Phosphatase 




3.37 1.06e-05 0.0051 RNA, U6 Small Nuclear 919, Pseudogene pseudogene 
RPS6P15 3.01 2.82e-06 0.0024 Ribosomal Protein S6 Pseudogene 15 pseudogene 
RN7SL748
P 
2.44 1.59e-05 0.0061 RNA, 7SL, Cytoplasmic 748, Pseudogene pseudogene 
RPL10P4 2.33 2.88e-07 0.00051 Ribosomal Protein L10 Pseudogene 4 pseudogene 
RPL21P133 2.32 6.39e-07 0.0010 Ribosomal Protein L21 Pseudogene 133 pseudogene 
RN7SL290
P 
2.22 1.06e-05 0.0051 RNA, 7SL, Cytoplasmic 290, Pseudogene pseudogene 
OR5M4P 
2.21 4.97e-05 0.011 
Olfactory Receptor Family 5 Subfamily M 




2.19 1.58e-07 0.00036 RNA, U6 Small Nuclear 151, Pseudogene pseudogene 
RNU6-
135P 
2.19 1.29e-07 0.00034 RNA, U6 Small Nuclear 135, Pseudogene pseudogene 
RNA5SP11
6 
2.18 0.00085 0.046 RNA, 5S Ribosomal Pseudogene 116 pseudogene 
NUTM2D 2.13 0.00016 0.021 NUT family member 2D unknown 
RNA5SP54 2.06 8.49e-08 0.00030 RNA, 5S Ribosomal Pseudogene 54 pseudogene 
RN7SL865
P 
2.05 0.00074 0.043 RNA, 7SL, Cytoplasmic 865, Pseudogene pseudogene 
RPS29P8 2.00 8.69e-07 0.0012 Ribosomal Protein S29 Pseudogene 8 pseudogene 
 
Before RT was applied, eight genes were altered in patients with TSCC compared to controls (Table 
3). Five of these genes remained unaffected with subsequent therapy: LIFR, FKBP5, SPARCL1, 
MS4A4E, and PDGFRA.  
In response to treatment, we found nine downregulated genes. Eight of these genes were in the 
histone cluster family, including HIST1H3B, HIST1H2BM, HIST1H3C, HIST1H3H, HIST1H1A, 
and HIST1H1B; and one, MKI67, was a marker of Ki-67 proliferation. Five genes were upregulated. 
Of these, two were related to apoptosis, MDM2 and EDA2R, and one, POLH, encoded a 
transcriptional DNA-directed polymerase (Table 3).  
On day 21 after the last RT application, we found 11 altered genes compared to baseline (Table 3). 
Most were pseudogenes, including ANKRD20A5P, ANKRD20A11P, ANKRD20A9P, and 
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CYP4F34P (downregulated); and noncoding RNAs, CCAT1 and MIR31HG. The MIR31HG RNA 
was upregulated only among patients with TSCC that received cisplatin. IL1R2 (downregulated) 
encoded a cytokine receptor of the interleukin 1 receptor family. SCIN (downregulated) encoded a 
regulatory protein involved in exocytosis. Immunohistochemical analysis results (Fig 2) showed 
reduced expression in epithelial cells, but not in the salivary glands.  
Fig 2. Immunohistochemical analysis of mucosal tissue expression of scinderin. Oral buccal 
mucosa section (15 magnification) stained with an SCIN antibody. (a) High scinderin expression is 
evident in mucosa from a control individual (patient CON05). (b) Low scinderin expression is 
evident in mucosa from a patient with tonsil squamous cell cancer (patient TSCC07); the biopsy 
was acquired Day20. SCIN encodes a regulatory protein involved in exocytosis and we expected to 
se downregulation in salivary gland tissue, however epithelial cells were heavily stained in the 
healthy control group.  
 
When gene expression profiles of the buccal mucosa were compared between UM and NM 
samples, we found no differentially expressed genes (adjusted P < 0.05) in either blood or mucosa. 
However, one gene, LY6G6C, tended to be expressed at low levels (FC -3.78; adj. P = 0.0995) in 
UM baseline biopsies (Fig 3, Table 3).  
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Fig 3. Expression of LY6G6C in mucosa. Dot plot shows expression of LY6G6C, at baseline (Day 
0), after 7 days of RT (Day 7), and 20 days after the last RT session (Day 20), among patients that 
developed ulcerative mucositis (red) or mild/no mucositis (green), and in controls (blue). Patients 
with mild/ no mucositis exhibited an upregulation of LY6G6C. LY6G6C encodes a surface 
immunoregulatory protein expressed on mucosal dendritic cells.  
 
We found 12 downregulated and 17 upregulated genes in blood samples from the TSCC group 
compared to the control group (Table 4). These genes were dominated by small nuclear RNAs 
(snRNAs), e.g., RNU6-620P and RNU6-622P, and a dot plot of these two selected genes is shown 
in  Fig 4.  
 
Fig 4. Expression of RNU6-620P and RNU6-622P in blood cells. Dot plot shows expression of 
RNU6-620P (FC-x11.8; P=5.80e-80) and RNU6-622P (FCx7.3 P=8.62e-05) at baseline (Day 0), 
after 7 days of RT (Day 7), and 20 days after the last RT session (Day 20), among patients that 
developed ulcerative mucositis (red) or mild/no mucositis (green). Expression in normal controls is 
indicated with blue circles. These genes encode small nuclear RNAs, which are non-protein coding 
genes. Patients with TSCC expressed a significant different level of both genes compared to healthy 
controls.  
 
We clustered the expression levels of snRNAs, regardless of fold-changes according to P-value, and 
observed a distinct division between patients with TSCC and healthy controls (Fig 5). We found no 
differentially expressed genes in blood samples between baseline and day 7 or day 20.   
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Fig 5. Small nuclear RNA (snRNA) clustered according to P value.  The expression of snRNA 
regardless of fold change was clustered according to P value, showing a distinct division between 
patients with TSCC and healthy controls.  
Discussion 
This study aimed to validate our clinical pilot study set-up and demonstrate its potential for 
identifying pathogenic variables or biomarkers for molecular mucositis. In response to RT, we 
identified several altered genes in the mucosa, but no differentially expressed genes in the blood 
cells. Furthermore, the identified genes were not correlated to the grade of clinical mucositis. 
Furthermore, we found that although all patients with TSCC were diagnosed with a localized solid 
epithelial tumor, and the biopsies from the study group was harvested from clinically healthy buccal 
mucosa, the mucosal tissue and blood cells had different gene profiles compared to healthy controls 
before RT.  
RT effects on mucosal gene expression  
Several studies have described the molecular effects of radiation on normal tissue, but no studies 
have described effects on gene expression levels [19]. Generally, short-term alterations include 
increased levels of p53 and other apoptotic markers (e.g., Bcl-2 and Mcl-1) [14,32], increased 
numbers of inflammatory cells (CD68-positive macrophages and other leukocyte subtypes), and 
alterations in inflammatory markers (e.g., NF-kB and COX-2) [32-35]. The epithelium begins to 
regenerate after one week of radiation, confirmed by the identification of cell proliferation markers, 
Ki-67 and [3H]-TdR , and by the increased expression of keratins (keratins 1, 6, 10, 16) [37]. Over 
the long term, RT caused different distribution patterns of adhesion molecules and macrophage 
subpopulations, compared to pretreatment specimens [38].  
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The present pilot study identified markers of apoptotic activity. EDA2R was upregulated in the 
mucosa 7 days after RT initiation, compared to its pretreatment status. EDA2R encodes the 
ectodysplasin A2 receptor, a transmembrane protein in the tumor necrosis factor receptor 
superfamily. Upon stimulation, this receptor activates the NF-ĸB and JNK apoptotic pathways . In 
addition, six members of the histone cluster family were downregulated, which indicated DNA 
damage. Histones are basic nuclear proteins responsible for nucleosome structure. Previous studies 
in cell lines have described histone downregulation in response to RT [40].  
In parallel, the MDM2 oncogene (MDM2) was upregulated. MDM2 encodes an E3 ubiquitin ligase, 
localized in the nucleus, and is regulated transcriptionally by p53. In turn, E3 ubiquitin ligase 
mediates the ubiquitination of p53, and thereby, inhibits p53-mediated cell-cycle arrest and 
apoptosis [41]. In addition, the upregulation of POLH, a polymerase that replicates UV-damaged 
DNA, indicated a DNA defense mechanism. Thus, we identified both inducers and inhibitors of 
apoptosis and DNA damage, consistent with findings reported in previous preclinical studies. 
Proliferation-related genes were also altered. MKI67, which encodes Ki-67, a nuclear protein that is 
essential for cellular proliferation, was downregulated after 7 days of RT. This finding contrasted 
with findings from a previous study on human mucosa [32]. However, KRT16 was upregulated. 
KRT16 encodes keratin16, a protein characteristic of early differentiated epithelial cells. This short-
term change indicated continuous epithelial proliferation [42]. This finding was also reported in a 
previous study [37].  
SCIN encodes a calcium ion- and actin filament-binding protein with a regulatory function in 
exocytosis [43]. We expected SCIN to be associated with salivary gland function because of the 
connection to exocytosis function and prior studies have reported histological changes in radiated 
salivary glands, including atrophy, edema, cell death, and fibrous tissue formation [44]. However an 
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immune histochemical stain for SCIN revealed that the presence was seen in the epithelial cells (Fig 
2).  
A potential biomarker for the grade of clinical mucositis  
When we compared samples from three patients with NM to samples from 4 patients with UM, we 
found that LY6G6C (lymphocyte antigen 6 complex, locus G6C) was upregulated (x3.78; 
P=0.0995) in NM before treatment, although this finding was not statistically significant (Fig 3). 
LY6G6C belongs to a cluster of leukocyte antigen-6 genes linked to the major histocompatibility 
complex–class II. This complex is located at the cell surface, where it is involved in immune-
mediated signal transduction.  
In a previous study, we showed that two members of the major histocompatibility complex–class II 
gene family, HLADR-B1 and B5, could potentially predict UM in patients with multiple myeloma 
[20]. We therefore hypothesize that HLA-based immunity protect against tissue inflammation 
during treatment in both these disease categories. Because mucositis may be considered an 
inflammatory state, those findings might add to our molecular understanding of why RT induces 
severe mucositis in some patients. 
Pretreatment gene signature of TSCC 
In mucosa, we found that TSCC induced a specific gene signature different from controls (Table 3). 
In particular, we found that TSCC induced changes in the expression of leukemia inhibitor factor 
receptor-alpha (LIFR), platelet-derived growth factor receptor-alpha (PDGFR), and secreted protein 
acidic and cysteine rich-like protein (SPARCL) genes. First, this signature was present in clinically 
normal-appearing oral mucosa located at a distance from the tonsil tumor. Second, the signature 
was expressed independently of alcohol consumption, smoking habits, and p16 overexpression in 
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the tumor, in addition to other clinical features. Third, this signature remained practically 
unchanged throughout RT.  
LIFR, a transmembrane receptor protein of the type 1 cytokine receptor family, is involved in 
cellular differentiation, proliferation, and survival; moreover, it inhibits the p53 apoptotic pathway. 
Low expression has been detected in various human cancers [45]. However, LIFR has been 
identified as both a suppressor and a promoter of carcinogenesis. PDGFR encodes a cell-surface 
tyrosine kinase receptor that binds platelet-derived growth factor family members. The receptor 
complex activates pathways involved in cell migration and chemotaxis during wound healing [46]; 
additionally, mutations in PDGFRA play an active role in cancer development [47]. Finally, 
SPARCL is involved in extracellular matrix synthesis. It was downregulated in number human 
cancer types [48]. It remains unclear why these genes, which are involved in cellular differentiation, 
wound healing, and extracellular matrix formation, are downregulated in clinically normal-
appearing mucosa acquired from patients with TSCC. Future studies should investigate whether this 
phenotype might indicate increased susceptibility to malignant transformation.  
The GGE analysis of blood samples revealed a large array of snRNA-type pseudogenes. Of these, 
RNU6-620P was downregulated 11.8-fold (P=5.80e-80) and RNU6-622P was upregulated 7.3-fold 
(P=8.62e-05) compared to controls. A cluster analysis of the expression of snRNAs and other 
noncoding RNAs in the blood revealed that distinctly different clusters of noncoding RNAs were 
associated with TSCC and controls (Fig 5). The protein coding genes did not show the same 
distinction.  
CONCLUSION 
In this pilot study, we described a gene signature expressed by mucosal tissue and circulating 
peripheral blood cells from patients with TSCC in response to RT. RT caused molecular alterations 
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related to apoptosis, DNA damage, DNA repair, and proliferation. However, these alterations were 
independent of clinical mucositis severity. Furthermore we identified a potential protective 
biomarker for ulcerative mucositis. Based on these results, we concluded that our model was 
feasible, and the data will be useful in designing a prospective clinical validation trial for 
characterizing mucositis at the molecular level and identifying predictive biomarkers. 
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Background: Mucositis is a frequent clinical complication to chemotherapy among patients with 
acute myeloid leukaemia (AML), however, the molecular mechanisms are not fully understood. 
Here our first goal is to present molecular data and conclusions from a pilot study of global gene 
expression (GGE) in human mucosa biopsies before, during and after induction treatment for AML. 
Our second goal is to compare the mucosa tissue GGE profile of AML patients with multiple 
myeloma (MM), and tonsil squamous cell carcinoma (TSCC) profiles.  
Materials and Methods: Six of nine primary included de novo AML patients delivered three 
consecutive buccal biopsies for analysis: before ADE (Cytarabine/Daunorubicin/Etoposide) 
induction therapy (day0), day 3 of treatment (day3) and before initiation of second induction 
therapy (day27). Buccal biopsies from nine healthy individuals served as controls (CON). Patient’s 
clinical characteristics including mucositis assessment were registered and correlated to gene 
expression.   
Results: Before treatment, RNU6-996P, a non-coding small nuclear RNA, was significant 
upregulated in AML compared to normal CON mucosa. In response to chemotherapy, genes with 
DNA repair, transcription and cell growth regulation were altered: POLH, HIST1H1, HIST1H2BM; 
and NOTCH1. Most important principal component analysis of pre-treatment GGE revealed 
differences between MM and AML or TSCC mucosa tissues.  
Conclusions: Therapy-induced molecular changes in the mucosa of patients with AML were 
dominated by DNA damage and repair genes. Most important the mucosal gene expression from 






Mucositis is a dose reducing side effect in the treatment of patients with acute myeloid leukaemia 
(AML), a blood cancer characterized by accumulation of abnormal blasts in the marrow that 
interfere with normal haematopoiesis and infiltrate the blood with immature blasts [1,2]. One year 
survival rate is around 70 % for patients less than 60 years, and far less, approximately 50 % for 
older patients following induction therapy [1]. The standard treatment of AML consists of a 
combination of Cytarabine, Daunorubicin, and Etoposide (ADE induction treatment). Often severe 
side effects associated to mucositis shorten or decrease planned treatment intensity. To reduce oral 
symptoms and febrile episodes during treatment, removal of inflammatory oral conditions prior to 
cancer treatment was recognized early in this patient group [3,4] in addition to prophylaxis towards 
reactivation of virus or opportunistic bacteria [4,5].  
The molecular mechanisms causing the diversity in clinical expression of mucositis during cancer 
treatment, has been studied in animal models and only few studies on the molecular changes during 
cancer therapy in human mucosa exists [6]. Preventive agents or interventions that have proven well 
when tested in animal models, fails to show any benefits in the clinic. At present, international 
recommendations for prophylaxis and treatment of mucositis are few and consist primarily of 
palliation of pain and infection control [7].  
In the present pilot study, we aimed to identify initial changes in gene expression in mucosa 
biopsies from a cohort of patients with AML during ADE induction treatment. Furthermore, we 
wanted to compare pre-treatment mucosa gene expression profiling in patients with AML with two 
earlier comparable studies on patients with multiple myeloma (MM) and tonsil squamous cell 




MATERIALS AND METHODS 
Patients 
We recruited 9 patients with AML at age 18 or above, cancer treatment naïve and without 
uncontrolled additional disease, from the Haematological Department, Aalborg University Hospital, 
Denmark from September 1st, 2010 to April 30st 2013. We also included 9 healthy, non-smoking, 
individuals as controls (CON) [8]. Of the nine patients with AML, five patients had all three 
biopsies taken, and one patient only 2 biopsies after which the consent was withdrawn. One patient 
was referred to intensive care after the first biopsy and was removed from the protocol for ethical 
reasons. Two patients withdrew their consent after the first biopsy. This resulted in six eligible 
patients with AML for the planned molecular mucosa studies.  
The first biopsy was obtained immediately before start of induction therapy (day0); the second 
biopsy was obtained after 3-4 days of therapy (day3); and the third was obtained 19-47 days after 
the last chemotherapy during an outpatient control visit (day21). A detailed study plan is shown in 
Figure 1. The clinical protocol was approved by The Committee on Health Research Ethics of 
Northern Denmark (N-20100022) and an informed written consent was obtained from all included 
patients in accordance with the Declaration of Helsinki.  
All patients underwent full initial medical evaluation including medical history and clinical 
examination, and characteristics including age, gender, Eastern Cooperative Oncology Group 
(ECOG) performance status at baseline, smoking habits (smoking more than 10 cigarettes per day), 
alcohol consumption (drinking more than 21 units of alcohol weekly), were registered.  Patients 
were screened for dental infections and, if indicated, these infections were removed prior to 
chemotherapy. AML patients received Cytarabine (100mg/m2) and Daunorubicin (50mg/m2) for 5 




Etoposide (100mg/m2) day 1, 3 and 5, for details on treatment see Table 1. Patients received 
antiviral, antifungal and antibacterial treatment according to department protocols. The clinical 
characteristics and demographics of the patients with AML appear in Table 1.   
Mucositis assessment 
Daily, during hospital admission, oral mucositis (OM) status was recorded according to WHO oral 
toxicity assessment worksheet (Quinn 2007), which included registration of subjective symptoms 
(ability to eat solid food and pain score) and objective findings of mucositis signs (erythema or 
ulceration). Grades 0 and 1 indicated none or very mild mucositis (NM) and grades 2-4 indicated 
ulceration and pain of increasing severity (UM).  
Collection of mucosa  
We refer to the methods used in our previous work [8]. In short, a lens-formed 5-mm biopsy was 
harvested in a standardized manner and the wound tightly sutured. One half of the biopsy was 
secured for GGE and immediately embedded in RNAlater™, and the other half was fixated and 
embedded in paraffin for histochemical staining.  
Gene expression profiling (GEP) procedure 
We refer to a detailed description of the methods used in our previous study [8]. In brief, for 
analysing mucosa, we used the Affymetrix GeneChip Human Exon 1.0 ST Arrays with the 
Affymetrix GeneChip WT Terminal Labeling and Controls Kit (P/N 901524). CEL files were 
generated with Affymetrix GeneChip Command Console Software and deposited at the NCBI Gene 
Expression Omnibus repository, under number GSExxxxx (to be uploaded).  
Statistical analysis  





Estimation of power size: To identify genes that varied more than two fold between test points with 
a false discovery rate (FDR) of less than 0.05% and a power of 90%, we applied the method 
described by Lee and Whitmore [12] implemented in the R-package size-power (Qui 2008). The 
results indicated that 10 patients in each group was sufficient.  
Data pre-processing: The CEL files produced by the Affymetrix Expression Console were pre-
processed and summarized at the gene level using the RMA algorithm with the Bioconductor 
package affy using custom CDF-files [13]. This pre-processing resulted in the expression levels of 
38,830 genes for each exon array annotated with Ensembl gene identifiers. 
Detection of differential expression: With patient ID as a cluster variable, using the limma-package, 
a mixed linear model and empirical Bayes approach were performed to test for significant 
differences in gene expression between the second biopsy/blood test and baseline, and between the 
third biopsy/blood test and baseline [14]. To test for significantly differentially expressed genes 
between baseline and CON, an unpaired t-test was performed using limma. Patients additionally 
were divided into two groups based on mucositis status (UM or NM), and significantly 
differentially expressed genes between the two groups also were detected using limma for each time 
point. 
The FDR-adjusted P values were controlled using the Benjamini–Hochberg method [15] for each of 







The clinical characteristics and demographics of the included patients are shown in Table 1. The 
AML and CON groups were comparable in age (AML: 65.5 years (range 58-75); CON: 58 years 
(range 47–78) and gender (AML: female 3/6; CON 4/9). Two of six AML patients were smokers, 
not any of the AML patients consumed more than 21 units of alcohol weekly. AML subtype 
according to the FAB classification (French-American-British classification of AML) [16] was 
registered: two M2, two M4, one M5 and one M6 . ECOG (1.2 (range 1-2), BMI (25.4 (range 21.4-
29.3). Finally, the individual treatment was noted.  
The clinical data during treatment, including mucositis assessment is shown in Table 2. The 
patients experienced clinical mucositis with an average score of 1.3 (range 0-3) and two patients 
experienced ulcerative mucositis. One patient responded completely while five relapsed, of these 
only one survived. Overall survival was 2.7 yrs. (range 1.5-4.3 yrs.); for the UM group 3.9 yrs. 
(range 3.4-4.3 yrs.) and for the NM group 1.9 yrs. (range 1.5-4.2 yrs.). Event free survival for the 
whole group was 1.1 yrs. (range 0-4.0 yrs.); for the UM group 2.9 yrs. (range 1.5-4.3 yrs.) and for 
the NM group 0.3 yrs. (range 0-1 yrs.).  
Gene expression analysis of the mucosa samples  
All biopsies produced evaluable gene profiles. Pre-treatment, two genes were differently expressed 
RNU6-996P and LINC01975 were significant upregulated in AML compared to normal CON 
mucosa. 
In response to treatment, we found four genes differently expressed: two genes of the histone cluster 




directed polymerase and NOTCH encoding a membrane protein responsible for intercellular 
signalling that regulates interactions between physically adjacent cells, were upregulated (Figure 2, 
Table 3)  
As illustrated in Figure 3 the gene expression of LINC01975 (left) and RNU6-996P (right) before 
(Day0), after 3-4 days of chemotherapy (Day3), and before initiation of the second induction 
therapy (Day27) indicate a potential UM predictive biomarker.  
Pre-treatment gene profiling in AML compared to independent cohorts of MM and TSCC 
We merged expression data from two cohorts of mucosa from patients with multiple myeloma 
(MM) [8], tonsil squamous cell cancer (TSCC) [19] and the AML cohort to perform a principal 
components analysis as illustrated in Figure 4. Each patient delivered three consecutive biopsies 
before, during and after therapy. Patients cluster according to disease indicating that disease is the 
major contributor to the variation in gene expression of the mucosa samples and not the treatment or 
grade of mucositis.  
 
DISCUSSION 
AML is a heterogonous cancer of the blood  with subtype classification  and a moderate survival 
rate [1,16]. In previous similar pilot-study set-up on patients with multiple myeloma respectively 
with tonsil squamous cell cancer, we identified biomarkers for severe mucositis and identified a 
range of upregulated genes of the apoptotic and inflammatory pathways in response to treatment. In 
this study, only a few genes were differentially expressed in response to treatment. This may be due 
to the heterogeneous treatment regimen: to patients received only Cytarabine (an antimetabolic 




(also a topoisomerase II inhibitor); one patient received both Cytarabine, Daunorubicin and 
Mylotarg (a monoclonal antibody against CD33) and one patient received all four entities. At the 
time of the second biopsy patients had revived an average of 3.5 days of treatment (range 3-5) 
involving the above-mentioned drugs. Of the genes identified, POLH encodes a specialized DNA 
polymerase that accurately replicates UV-damaged DNA was also upregulated in the MM and 
TSCC group. Members of the histone cluster family were downregulated, this was also seen in the 
TSCC cohort. NOTCH1 (upregulated) a cell membrane protein involved in cell signalling between 
adjacent cells was only upregulated in the AML cohort. POLH and NOTCH1 seem to be more 
upregulated in the non-mucositis group as illustrated in Fig2; this tendency was not obvious in 
TSCC and MM cohort.  
Previously only one study applied gene expression to human tissue harvested from only three 
patients with AML [18]. Clinical data on mucositis was collected, however this information was not 
correlated to the microarray data. Nevertheless, in response to therapy, eight significantly altered 
genes was identified; among these, the gene that encodes argininosuccinate synthase 1 (ASS1) was 
three-fold downregulated; argininosuccinate synthase 1 suppresses nitric oxide production, and 
consequently, promotes p53-mediated apoptosis. Moreover, they found that a gene encoding a zinc 
transporter (SLC39A6) was three-fold upregulated. The zinc transporter is involved in the epithelial-
mesenchymal transition and tissue repair. We did not identify similar genes in our material.  
This pilot study has together with our two other cohorts shown that disease specific transcriptomes 
exist has generated hypothesis that mucositis at the molecular level is heterogeneous and dependent 





Therapy-induced molecular changes in the mucosa of patients with AML was associated by DNA 
damage and defence genes. A PCA analysis of mucosal gene expression from three independent 
cancer cohorts showed that the major contributor to the variation in gene expression of the mucosa 






TABLE AND LEGENDS 
Table 1. patients characteristics and demography at entrance to the study 
Patient Age Gender ECOGa BMIb Smoc Alcd FABe  Treatment 
AML01 58 m 1 29.3 0 0 M6 Cy 10 days 
Da 3 times 
Mylo 
AML02 69 m 1 26.8 1 0 M2 Cy 8 days 
Da 3 times 
Etop 4 days 
AML04 59 f 1 21.4 0 0 M5 Cy 8 days 
Da 3 times 
Etop 4 days  
Mylo 
AML05 58 f 1 23.8 0 0 M4 Cy 10 days 
Da 3 times 
Etop 5 days 
AML07 75 f 1 27.1 0 0 M2 Cy 5 days 
Da 2 times 
AML09 74 m 2 23.9 1 0 M4 Cy 5 days 
Da 2 times 
 
Abbreviations: a=Eastern Cooperative Oncology Group performance status; b=body mass index; 
c=smoking more than 10 cigarettes per day; d=drinking more than 21 units of alcohol weekly; 
e=FAB: French-American-British subtype classification; Cy = Cytarabine 100mg/m2 twice daily; 
Da = Daunorubicin 50mg/m2 once every second day; Etop = Etoposide 100mg/m2 once daily. Mylo 
















follow up  
 
Patients with ulcerative mucositis 
AML01 3 3 41 MDS 
AML 
3.4 1.5 dead 
AML02 3 4 19 no 4.3 4.3 CR 
 
Patients with  no/mild mucositis 
AML04 0 4 No 3rd 
biopsy 
AML 4.2 1.0 relapse 
AML05 0 3 22 AML 1.5 0 dead 
AML07 1 3 27 AML 1.5 0 dead 
AML09 1 5 27 AML 1.5 0 dead 
 
Abbreviations: a= Mucositis estimated according to WHO [17]; b=number of days from initiation 
of induction therapy to second biopsy; c= number of days from end of first induction therapy to 
third biopsy. The third biopsy was secured immediately before initiation of second induction 
treatment. d=overall survival estimated as years from diagnosis/enrolment into study until death; 
c=event-free survival estimated as years from diagnosis/enrolment into study to disease 







Table 3 Genes altered more than 1.5 fold (P < 0.05) in the buccal mucosa of AML patients  
Gene symbol FC p-value adj. p-
value 
Qualified GO term  Function 
Baseline versus healthy controls 
RNU6-996P 2,04 2,28E-07 0,0067 RNA, U6 Small Nuclear 996, 
Pseudogene 
unknown 
LINC01975 1.66 2.33e-06 0.030 Long Intergenic Non-Protein 
Coding RNA 1975 
unknown 
Day 2 versus baseline 
HIST1H1A -3.20 8.08e-10 3.18e-05 Histone Cluster 1, H1a transcription 
HIST1H2BM -2.83 2.48e-06 0.024 Histone Cluster 1, H2BM transcription 
POLH 2.18 1.97e-06 0.024 Polymerase; DNA directed transcription 







Figure 1. A detailed illustration of the study design. 
 
The 1st biopsy was collected before initiating induction therapy (Day0); the 2nd after 3-5 days of 
chemotherapy (Day3); and the 3rd biopsy was harvested at an out-patient control visit 19-41 day 
after the last chemotherapy session (Day27), just before initiating the second induction treatment. 








Figure 2 Gene expression in the mucosa of AML during ADE induction treatment.  
 
 
Gene expression in the mucosa of patients with AML receiving ADE induction treatment. before 
(Day0), after 3-4 days of chemotherapy (Day3), and before initiation of second induction therapy 
(Day27). Red = UM; green = NM; blue = CON. First row: genes of the histone family: HIST1H1A 
and HIST1H2BMB. Second row: POLH and NOTCH1. Although not statistically significant, there 
was a tendency towards upregulation of POLH and NOTCH1 in response to treatment among the 
patients that did not develop mucositis, see arrows. These genes were also differently expressed in 




Figure 3 Gene expression in the mucosa of patients with AML before treatment.  
 
Gene expression of LINC01975 (left) and RNU6-996P (right) before (Day0), after 3-4 days of 
chemotherapy (Day3), and before initiation of the second induction therapy (Day27). Red = UM; 
green = NM; blue = CON. The level of expression seems to normalize in response to treatment in 










Figure 4 A and B. Principal components analysis of MM, TSCC, and AML 
Three cohorts of patients with multiple myeloma (MM) = red (receiving high dose melphalan); 
AML = green (receiving ADE induction treatment); and tonsil squamous cell cancer (TSCC) = blue 
(receiving radiation treatment). A) Each patient delivered three consecutive biopsies before, during 
and after therapy. B) Only data from the 1st pre-treatment biopsies. Patients cluster according to 
disease indicating that disease is foremost contributor to the variation in gene expression of the 
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